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When the International Federation of Red Cross and Red Crescent Societies was founded in 1919, a major goal was to
‘spread the light of science and the warmth of human sympathy into every corner of the world’, particularly in the field
of health care. Today, the message of the International Federation is the same as it was 84 years ago. 
Sound scientific evidence and human compassion must be the guiding force in our response to the humanitarian chal-
lenges we face. But sadly, political imperatives, donor demands, and ignorance and fear continue to impede the work of
preventing and alleviating suffering and protecting human dignity.
Nowhere, is the gap between a humanitarian response based on compassion and scientific evidence and the inadequacies
of actual practices, more evident than in the inhumane treatment of injecting drug users. These people are in need of care
and compassion, and real alternatives. Instead, they routinely face harassment, stigmatization, violence and social exclu-
sion. The stigma attached to drug use is causing further marginalization of this most vulnerable group and this is direct-
ly impeding efforts to prevent the spread of HIV.
Forcing people who use drugs further underground and into situations where transmission of HIV/AIDS is more likely,
and denying them access to life-saving treatment and prevention services is creating a public health disaster. This happens
even though the evidence from scientific and medical research on best practices and cost benefit analyses is overwhelm-
ingly in favour of harm reduction programming. This includes needle exchange, drug substitution treatment and con-
dom distribution as part of the response to HIV/AIDS.
The message is clear. It is time to be guided by the light of science, not by the darkness of ignorance and fear. If we are
to put a stop to this trend, communities need to treat drug users in a more humane way, respecting them as people with
rights and needs. The Red Cross and Red Crescent is well placed to advocate for the just treatment of drug-users and for
harm reduction in general. Our respected name and emblem enable us to reach a wide audience the world over and our
compassion and concern for human health and dignity have earned us the trust of the most marginalized groups.
From this perspective, it is very appropriate that the theme of the International Conference of the Red Cross and the Red
Crescent in 2003 is Protecting Human Dignity. The Agenda for Humanitarian Action emerging from that conference is
one more step in the promotion of humanitarian values, and building the climate to reduce marginalization so the risk
and impact of HIV/AIDS and other infectious diseases can be reduced. It demonstrates that the Red Cross and Red
Crescent values every life by extending humanitarian assistance to where is it most needed, without discrimination.
Juan Manuel Suárez del Toro Rivero
President
International Federation of Red Cross and Red Crescent Societies
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Abbreviations
The purpose of this document is to outline the rationale for harm reduction programmes. It outlines
generic approaches that National Societies can adapt to the realities of their countries in the devel-
opment and implementation of harm reduction programme and in conducting advocacy for the
acceptance and realization such programmes.
The guidelines are designed for National Society staff and volunteers working at all levels and for
those involved in planning, organizing, implementing and assessing harm reduction programmes, as
well as those involved in advocacy. The document also sets out ideas related to programme develop-
ment, ways to facilitate programme implementation, as well as ways to plan and realize advocacy
activities.
These guidelines were compiled at the request of the Governing Board. The request was made at the
same meeting at which the board adopted the International Federation’s HIV/AIDS policy, in 2002.
It is expected that the guidelines will be used to give strategic direction to all National Societies
intending to address the challenges of HIV/AIDS among injecting drug users (IDUs). The docu-
ment is based on an extensive literature review related to the impact of harm reduction programmes
and to the lessons learned concerning the implementation of harm reduction programmes by vari-
ous organizations over the last decade.
These guidelines are part of the International Red Cross and Red Crescent Movement’s response to
the HIV/AIDS epidemic and should be read in conjunction with other relevant International
Federation documents, including:
■ the 2003-2005 International Federation global programme: Reducing household vulnerability
to HIV/AIDS and other infectious diseases 1, and update 2003;
■ AIDS, Health and Human Rights manual; 2
■ Orphans and other children made vulnerable by HIV/AIDS. Principles and Operating
Guidelines for Programming; 3
■ Community home-based care for persons living with HIV/AIDS: A framework for National
Society programming; 4
■ the Fundamental Principles of the International Red Cross and Red Crescent Movement; and
■ Operational Guidelines for Planning.
There are other supporting International Federation documents:
■ The International Federation HIV/AIDS Policy, 2002, approved by the Governing Board, pro-
vides a framework to support National Societies in the implementation of HIV/AIDS related
activities. It states, “Guided by sound public health and humanitarian principles, promote and
where appropriate facilitate harm reduction strategies for high risk behaviours and traditional
practices, including advocacy for law reform as necessary”.5
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1 http://www.ifrc.org/what/health/hivaids/vulnerability/index.asp.
2 Publications, Geneva: International Federation of Red Cross and Red Crescent Societies, Harvard School of Public Health, 1995, available in English, French and Spanish.
To order, e-mail guidera@ifrc.org.
3 http://www.ifrc.org/what/health/tools/index.asp#hivaids.
4 http://www.ifrc.org/what/health/tools/index.asp#hivaids.
5 http://www.ifrc.org/who/policy/hivaids.asp.
6 http://www.ifrc.org/cgi/pdf_berlin.pl?health.pdf.
7 http://www.aprc.net/map2002.htm.
8 http://www.ifrc.org/what/health/hivaids/antistigma/declaration.asp. 
9 Millennium Declaration signed by 189 countries, September 2000. www.un.org/documents/ga/res/55/a55r2002.pdf. 
10 UNGASS, Paragraph 34 http://www.unaids.org/UNGASS/.
11 See footnotes 50, 51 and 52 and text.
12 UN Economic and Social Council, Commission on Narcotic Drugs, forty-fifth session, E/CN.7/2002/L.3/Rev. 1, 12 March 2002.
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■ The European National Societies Conference in Berlin, April 2002, unanimously supported
implementing harm reduction strategies, marking a major step forward to addressing the rapid
increase in infection in the region.6
■ The Manila Action Plan, which concluded the Manila Conference in December 2002, requires
all National Societies in the Asia, Pacific and Middle East regions to develop culturally appro-
priate harm reduction programmes.7
■ The International Federation 13th General Assembly Declaration of 2001 states, “Recognizing
that the HIV/AIDS epidemic is a devastating health and socio-economic crisis; following the
Fundamental Principles of humanity, impartiality and neutrality; acknowledging the commit-
ment to serve and involve the most vulnerable people, including people living with HIV/AIDS;
and recognizing the need to build partnerships at all levels in order to be successful, the
Assembly declared that HIV/AIDS will be confronted through prevention, care, treatment and
support, and the promotion of dignity of those affected”.8
These guidelines are in conformity with:
■ the Millennium Declaration 9, Goal 6, in which states committed to halting and beginning to
reverse the spread of HIV/AIDS by 2015;
■ the Declaration of United Nations General Assembly Special Session on HIV/AIDS
(UNGASS), 2001, which recognized the work of the Federation. “Further acknowledging the
efforts of international organizations combating the epidemic, including the volunteers of the
International Federation of Red Cross and Red Crescent Societies in the most affected areas all
over the world.” 10 The Declaration also makes specific reference to harm reduction, drug using
behaviour, and stigma and discrimination 11; and
■ the United Nations Commission on Narcotic Drugs resolution on HIV/AIDS and drug abuse
which “recognizes that effective prevention, care and treatment strategies require behavioural
changes and increased availability of and non-discriminatory access to, inter alia, vaccines, con-
doms, microbicides, lubricants, sterile injecting equipment, drug therapy, including anti-retro-
viral therapy, diagnostics and related technologies, as well as increased research and develop-
ment, encourages Member States to strengthen efforts to reduce the demand for illicit drugs
and to ensure that a comprehensive package of prevention, education, treatment and rehabili-
tation measures are accessible to all individuals who use and abuse illicit drugs, including those
infected with HIV/AIDS, and encourages Member States to; implement measures that reduce
or eliminate the need to share non-sterile injecting equipment.12
The guidelines outline the epidemiological data concerning injecting drug use and HIV infection;
the increasing drug and injecting drug use; and needle sharing. The human rights, humanitarian and
public health rationales as well as cost effectiveness of harm reduction programmes are laid out.
Finally, information and possible activities for National Societies are outlined.
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People have used psychoactive substances since time immemorial. Consumption has been through
inhalation or smoking as well as ingestion of fluid or solid substances. Manufactured drugs and mod-
ernized methods of administration are relatively new phenomena beginning in the last decades of the
19th century. Needles and syringes are a relatively recent invention, now routinely used to adminis-
ter drugs in both medical settings as well as for many illegal drugs.
The availability of drugs, human curiosity, pleasure, peer pressure, economic deprivation, social and
religious traditions, a lack of objective information on drugs and their effects, psychological illness,
and possibly genetic factors, play roles in people's use and abuse of drugs. Substance use and abuse
are not isolated behaviours and failure to see them, possibly, as part of larger patterns of risk taking
may create barriers to effective interventions. In addition, IDUs are affected by problems such as
high rates of homelessness, unemployment, low educational levels and little information on HIV
and other health problems associated with injecting drug use.
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Over the past century, and increasingly in the last decades, governments in many countries have
adopted strict policies against the provision, sale and use of illegal drugs as well as on the possession
of drug use paraphernalia.13 The objective has been to create a society free of illegal drugs. At the
same time, most cultures accept other drugs of addiction such as tobacco, alcohol, quat, bettlenut
and caffeine. And these are used by governments to raise revenue through taxes, even though con-
clusive medical evidence exists that some of these drugs can cause serious social and health problems,
including death.
Since the early 1990s, the changed geo-political climate has seen the opening of borders which were
previously closed, creating new drug trafficking routes and markets, and opening up old ones. The
effects of these developments have been enhanced by the globalization of drug markets and distri-
bution networks, and by the increase of informal economies including the drug market as an
unwanted by-product of drug suppression activities. 
In spite of laws and governmental measures, such as intensive policing, imprisonment and, in some
countries, ‘war on drugs’, illegal drug use is on the increase. This approach, which includes impris-
onment and harassment by law enforcement agencies, drive many drug users underground, away
from social support services, including health services, making contact, providing HIV education
and prevention as well as and health care difficult.
In addition, legalistic approaches and government policies which aim at criminalizing the behaviour
of people who use drugs have created and reinforce the stigma and discrimination faced by people
who use substances. In some countries, this has been transferred to people living with HIV/AIDS
(PLWHA) or specifically to PLWHA who use drugs.
Furthermore, discrimination faced by IDUs can also be found in the medical setting. It has been
reported in many countries where there are HIV-positive IDUs, that doctors are refusing to proscribe
anti-retroviral (ARV) therapy to IDUs on the basis that they are unlikely to adhere to the compli-
cated drug regimes, which may result in the formation of drug resistant mutations of HIV, which in
turn will be transmitted to other drug using or sexual partners. Studies have shown that HIV-infect-
ed drug users who receive comprehensive assistance usually have good ARV adherence.14 Such pater-
nalistic and discriminatory approaches are compromising the health of HIV-positive as many HIV-
positive IDUs are delaying HIV treatment much longer than non-users. 
Finally, another problem faced by HIV-positive IDUs is pain management, since IDUs usually have
a very high tolerance for depressant drugs and need higher, not lower, dosages for effective pain 
management.
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13 United Nations Single Convention on Narcotic Drugs, 1961 aims to combat drug abuse by coordinated international action. There are two forms of intervention and con-
trol that work together. First, it seeks to limit the possession, use, trade, distribution, import, export, manufacture and production of drugs exclusively to medical and sci-
entific purposes. Second, it combats drug trafficking through international cooperation to deter and discourage drug traffickers. 
United Nations Convention on Psychotropic Substances, 1971, establishes an international control system for psychotropic substances. It responded to the diversification
and expansion of the spectrum of drugs of abuse and introduced controls over a number of synthetic drugs according to their abuse potential on the one hand and their
therapeutic value on the other.
United Nations Convention against the Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988, provides comprehensive measures against drug trafficking,
including provisions against money laundering and the diversion of precursor chemicals. It provides for international cooperation through, for example, extradition of drug
traffickers, controlled deliveries and transfer of proceedings http://www.unodc.org/unodc/un_treaties_and_resolutions.html.
14 IDUs taking part in methadone maintenance programmes have an increased adherence and long-term ARV success. Linking drug therapy programs with ARV treatment
and using directly observed therapy where possible may also contribute to antiretroviral success. Providing IDUs with frequent, careful medical and psychosocial follow-up
with constant reinforcement of the need for ARV treatment and the ability of the clinician to manage ARV-related side effects and potential toxicities are also keys to suc-
cess. Mulcahy F, Antiviral therapy and management of HIV in intravenous drug users, Program and abstracts of the Fifth Congress on Drug Therapy in HIV Infection,
Glasgow, Scotland. Abstract PL3.3, October, 2000.
Section 1.1
Injecting drug use and 
HIV epidemiological data
Many injecting drug users are occasional or opportunistic recreational users. They do not fit the
stereotype of the ‘drug addict’. However, such delineation does not protect recreational users from
HIV infection. Some individuals report being able to regulate their drug use for long periods 
and maintain work and family responsibilities, and this is referred to in the literature as ‘functional
drug use’. 
Nevertheless, it is clear that many people, even when they are well informed about the risks associ-
ated with drug use, continue to use them. Most individuals who are regular IDUs do become addict-
ed over time, and this often adversely affects their own lives, their partner’s and the community in
which they live. Recovery from drug addiction is at best a long-term process, usually involving
relapse. Considerable courage and support is needed to face the pain and personal growth involved.
It is clear that this recovery process usually needs to be undertaken voluntarily to be effective and
sustained.
Some of the worst public health problems associated with drug use involve the sharing of injecting
equipment. Of all the modes of HIV transmission, directly injecting a substance such as opiates like
8
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heroin, methadone or morphine, or other drugs such as cocaine, amphetamines, barbiturates, ana-
bolic steroids, antibiotics or vitamins contaminated with HIV into the blood stream is by far the
most efficient.
The risk of HIV infection or infection with other blood borne viruses such as hepatitis B virus
(HBV), hepatitis C virus (HCV) is not through drugs themselves, but rather their mode of admin-
istration. Some IDUs, frequently, others, occasionally, share needles and syringes or other equipment
used in the process of preparing drug mixes for injection. 
The sharing of contaminated drug injecting equipment and drug preparations is a highly efficient
means of spreading HIV. Usually, small amounts of blood enter the needle and syringe when drugs
are injected. In addition, the blood can then be transferred to other drug injecting equipment such
as ‘cookers’, filters and drug containers, as well as water used for mixing and rinsing. 
Only a small amount of infected blood is needed to pass on the virus from one drug user to anoth-
er, so any type of equipment sharing poses a high risk of HIV transmission. The worst situations for
the spread of HIV are when many IDUs are using the same needle and syringe, such as in the ‘shoot-
ing galleries’ of North America and with some ‘professional’ injectors in Asia, eastern Europe and
Latin America, as well as in prisons.
In the last decades, long standing patterns of drug injection in developed countries have been joined
by the emergence of injecting drug use in many developing countries. This has occurred even in
countries which were thought to be resistant to injecting because of their drug using tradition, cul-
tural behaviours, or religious or spiritual beliefs.15
In some developing countries, injecting is found in many social groups, in rural and urban areas, and
among township dwellers and hill tribes. The spread of injection has been followed by harmful
health and social consequences including the rapid spread of HIV infection among IDUs, now
reported in 114 countries of the 136 countries which report IDU, HIV transmission to sexual part-
ners and their children, economic costs to families and communities, and loss of liberty or life for
drug users from penal or community sanctions.
Currently, it is estimated that there are more than 10 million people globally who inject drugs. Of
these, 2-3 million people are estimated to be HIV-positive. This translates to an estimated 10 per
cent of HIV infections globally, resulting from shared injecting equipment. In 1992, the number of
countries which reported HIV infection associated with injecting drug use was 52. However, by
1999 this had increased to 114.16
Asia is estimated to have the largest number of injecting-drug-related HIV cases. Injecting drug use
is also a major factor in HIV epidemics in North America, western Europe and in parts of Latin
America, the Middle East and North Africa. In some eastern European countries, especially in coun-
tries of the former Soviet Union, shared injecting equipment is driving major HIV/AIDS epidemics
among young people, and many outreach programmes report rising numbers of sexually active
teenage drug users.
Injecting-drug-related HIV epidemics do not remain limited to injecting drug users. Most injecting
drug users are young, male and sexually active. They are likely to acquire or transmit the HIV virus
not only by sharing injecting equipment but also through sexual intercourse with regular or casual
partners. Injecting drug use also overlaps profoundly with the sex trade, with users often buying sex
or selling sex to finance their drug dependencies. 
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16 Report on the Global HIV/AIDS Epidemic, UNAIDS, 2002.
In 2000, in Hanoi, Viet Nam, 20 per cent of street-based female sex workers reported recent drug
injection, while 23 per cent of male injecting drug users bought sex. In Bangladesh, the correspon-
ding figures were 14 per cent and 50–75 per cent, respectively. Similarly, in some cities of the
Russian Federation and Ukraine, up to 30 per cent of female injecting drug users are also involved
in commercial sex work. More generally, recent studies in Donetsk, Moscow and St Petersburg have
revealed HIV prevalence rates of 13-17 per cent among sex workers. 
The remainder of this section draws on the findings of the 2002 Joint United Nations Programme
on HIV/AIDS (UNAIDS) Report on the Global HIV/AIDS Epidemic.
Asia
Throughout the region, injecting drug use offers the epidemic huge scope for growth. Upwards of
50 per cent of injecting drug users have already acquired the virus in parts of Malaysia, Myanmar,
Nepal, Thailand, Indonesia, and in Manipur in India. Very high rates of needle sharing have been
documented among users in Bangladesh and Viet Nam, along with evidence that a considerable pro-
portion of street-based sex workers in Viet Nam also inject drugs (a phenomenon detected in other
countries, too).
The epidemic in China shows no signs of abating. Serious localized HIV epidemics are occurring
among injecting drug users in nine provinces, as well as in Beijing municipality. The most recent
reported outbreaks of HIV among injecting drug users have been in Hunan and Guizhou provinces
(where sentinel surveillance among users has revealed HIV prevalence rates of 8 per cent and 14 per
cent, respectively).
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Eastern Europe and central Asia
Eastern Europe and central Asia have the unfortunate distinction of having the world’s fastest-grow-
ing HIV/AIDS epidemic. In recent years, the Russian Federation has experienced an exceptionally
steep rise in reported HIV infections. In less than eight years, HIV/AIDS epidemics have been dis-
covered in more than 30 cities and 86 of the country’s 89 regions. Up to 90 per cent of the regis-
tered infections have been officially attributed to injecting drug use, reflecting the fact that young
people face high risks of HIV infection as occasional or regular drug injectors. Also in the region, 70
per cent of HIV infections in Ukraine, 80 per cent in Belarus, 83 per cent in Kazakhstan and 84 per
cent in Moldavia are estimated to be the result of injecting drug use.
The HIV epidemic is growing in
Kazakhstan, where a total of 1,926 HIV
infections were reported as at June 2001. A
more substantial spread of HIV is now also
evident in Azerbaijan, Georgia, Kyrgyzstan,
Tajikistan and Uzbekistan. In the latter two
republics, recent evidence of rising heroin
use heightens concerns that they could be on
the brink of larger HIV/AIDS epidemics.
Already, a steep rise in reported HIV infec-
tions has been noted in Uzbekistan, where
620 new infections were registered in the
first six months of 2002 – six times the
number of new infections registered in the
first six months of 2001.
Reported HIV incidence is rising sharply
elsewhere. In Estonia, reported infections
soared from 12 in 1999 to 1,474 in 2001. Relative to population size, Estonia now has the highest
rate of new HIV infections in this region – 50 per cent higher than the Russian rate. A burgeoning
epidemic is also visible in Latvia. New reported infections rose from 25 in 1997 to 807 in 2001. A
further 308 new HIV cases were registered by the end of June 2002.
The other Baltic state, Lithuania, experienced a major HIV outbreak in one of its prisons, where 284
inmates (15 per cent of the total) were diagnosed HIV-positive between May and August 2002. This
confirms the important and often overlooked role of prisons in the spread of HIV in many coun-
tries of the region.
Latin America and the Caribbean
The spread of HIV through the sharing of injecting drug equipment is of growing concern in sev-
eral countries, notably Argentina, Brazil, Chile, Paraguay and Uruguay (in South America), the
northern parts of Mexico, and Bermuda and Puerto Rico (in the Caribbean). Injecting drug use
accounts for an estimated 40 per cent of reported new infections in Argentina and 28 per cent in
Uruguay. In both countries, an increasing number of women with HIV are either injecting drug
users or sexual partners of male drug users.
North Africa and the Middle East
Significant outbreaks of HIV infections among injecting drug users have occurred in about half the
countries in the region, notably in North Africa and in the Islamic Republic of Iran.
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In Iran, most HIV transmission is occurring among the country’s estimated 200,000-300,000 inject-
ing drug users, about 1 per cent of whom are believed to be living with HIV. High-risk behaviour is
widespread in this largely male population; about half of the users share injecting equipment, and as
many are believed to have extramarital sexual relations. According to some estimates, a significant
percentage (more than 30 per cent) of them is married. Yet condom use is very rare. In addition,
about 10 per cent of prisoners are believed to inject drugs and more than 95 per cent of them share
needles. HIV prevalence among imprisoned drug injectors was 12 per cent in 2001.
Developed countries
Most high-income countries are also contending with concentrated HIV epidemics, including in the
United States, where injecting drug use is a prominent route of HIV infection (accounting for 14
per cent of all reported HIV diagnoses). Reported HIV prevalence among injecting drug users in
Spain in 2000 was 20-30 per cent. In France, prevalence rates ranged between 10 per cent and 23
per cent. Portugal’s serious epidemic among injecting drug users accounted for more than half of the
newly diagnosed HIV infections in both 2000 and 2001, though the number of reported HIV infec-
tions among injecting drug users declined significantly in 2001.
Sub-Saharan Africa
Injecting drug use is a global phenomenon including, most recently, in Africa, which is also, increas-
ingly being used for the trafficking of heroin and cocaine. According to the 2001 UN Office on
Drugs and Crime (UNODC) World Drug Report, the opiate use prevalence in Nigeria was 0.3 per
cent. The joint study between the World Health Organization (WHO), the ministry of health and
the University of Ilorin on drug abuse concluded that injecting drug use with associated health con-
sequences was an emerging problem in Lagos, Nigeria. 
The knowledge base of the drug abusers on HIV was generally low; treatment and rehabilitation services
were few and non-affordable. HIV prevalence rate among the total sample of drug users was higher than
in the general population (9.8 per cent versus 5.4 per cent). There was no significant difference between
the HIV rates obtained for non-injectors and ever-injectors, however, female users were significantly more
likely to be HIV-positive compared with their male counterparts, regardless of their injecting status. 17
Injecting drug use has already been described as a major problem in Mauritius. Reports indicate
increasing numbers of IDUs in Kenya.18 And there is strong anecdotal evidence from Tanzania of an
evolving drug problem.19
Section 1.2 
Increases in injecting drug use
Coinciding in part with pressure on countries to submit to international restrictions on drug use,
illegal drugs are increasingly administered through injection, especially in regions where poverty,
homelessness, migration and other socio-economic problems are common. Several factors may be
important, including local drug production and transit, and unintended consequences of enforce-
ment activity and drug user migration. Such factors are in turn related to global drug markets,
income inequalities between nations, trade and cultural links, urbanization, social dislocation, mod-
ernization and internal political conditions.
Other reasons for the spread and increasing popularity of injecting are complex:
■ Injecting offers the most cost-effective way of using a drug – a smaller quantity of a given drug
is needed to achieve the same effect provided by another mode of administration.
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■ Injecting a drug is a faster route than other methods for achieving a high.
■ Drugs and injecting paraphernalia may be easier to conceal than other methods of taking drugs.
■ Injecting is often described as the ‘normal’ was of taking a given drug.
■ Injecting is the only way of using some preparations and there may not be a choice of prepa-
rations on the market.
■ There is a greater availability of a drug which can be injected.
■ Peer pressure to use drugs may occur as the drug-taking rituals can create a sense of social inclu-
sion.
■ There is a custom of injection for self medication.
■ There is an influence of migratory drug users.
■ There is increasing involvement in cultivation and manufacturing drugs.
■ People live in proximity to drug trafficking routes.
Efforts to discourage injecting and to avoid the associated
health and social costs are hampered by social, structural,
economic and political factors. These include: 
■ over investment in supply reduction rather than
demand and harm reduction; 
■ tough law enforcement against drug users; 
■ benefits to producer and transit countries from 
continued production and distribution;
■ populations with low levels of education; 
■ lack of access to media; 
■ poor transport and communications; 
■ competing health and social priorities; 
■ lack of medical and public health resources; 
■ lack of resources for treatment and harm reduction; 
■ marginalization and repression of drug users; 
■ national ‘immunity’ myths; and 
■ antipathy towards public health approaches to help
IDUs and social costs of drug use.
Section 1.3 
Sharing needles and syringes
The extent of HIV epidemics among IDUs and the speed with which a given epidemic spreads with-
in IDU communities, and thereafter into the general population, depends on the degree of social
mixing in the population. This includes the number of different people shared with, the degree to
which IDUs move between social networks, and how large these sharing networks are.
Given the wrong conditions, the transmission of HIV among IDUs can be rapid, with up to 40-90
per cent of all IDUs in a given community infected in a matter of months. This has happened in
places as geographically and culturally remote as New York, Milan, Edinburgh, Bangkok, Santos,
Odessa, Ho Chi Minh City, Yunnan Province in China and Manipur State in India.20
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17 World Drug Report, UNODC, 2001, in Assistance to country responses on HIV/AIDS associated with injecting drug use by the UN and other agencies, Report for the
Interagency Task Team on injecting drug use, 2003.
18 The prevalence rate of opiate abuse in Kenya is 0.1 per cent, World Drug Report, UNODC, 2001, in Assistance to country responses on HIV/AIDS associated with injecting
drug use by the UN and other agencies, Report for the Interagency Task Team on injecting drug use, 2003.
19 Assistance to country responses on HIV/AIDS associated with injecting drug use by the UN and other agencies, Report for the Interagency Task Team on injecting drug use, 2003.
20 Rhodes T, Stimson GV, Crofts N, Ball A, Dehne K and Khodakevich. L, Drug injecting, rapid HIV spread, and the ‘risk environment’: implications for assessment and response, 13
(suppl A), AIDS 1999; Ball AL, Rana S and Dehne KL., HIV prevention among injecting drug users: Responses in developing and transitional countries, 113, sup1:170-181, Public
Health Reports, 1998; Stimson G, Des Jarlais DC and Ball A (Eds), Drug Injecting and HIV Infection: Global Dimensions and Local Responses, London UCL Press, 1998.
Th
om
as
 M
or
le
y/
Ex
ile
 Im
ag
es
Some of the reasons for sharing needles and injecting paraphernalia include:
■ lack of information about associated risks of injection and about safe injection;
■ sharing behaviour as a form of bonding or as a culturally or socially accepted practice;
■ intoxication during injection;
■ lack of injecting skills, particularly during the initiation period;
■ fear of procuring or carrying injecting equipment because it is illegal or because of police
harassment;
■ difficulty in accessing new injecting equipment because of prohibition, physical isolation or
limited hours in which to procure it; and
■ lack of money to buy injecting equipment.
After more than two decades of experience in HIV transmission among IDUs, there are a number
of epidemiological, geographical and social factors that are known to contribute to the rapid spread
of HIV among injectors. These include:
■ the presence of HIV in the population;
■ a recent and rapid spread of injecting drug use;
■ proximity to drug supply routes;
■ widespread unemployment and economic dislocation;
■ social change;
■ regular sharing of injecting equipment among members of social networks;
■ high levels of mixing between social networks of injectors; and
■ sale and distribution of drugs in syringes.
The dual problems of injecting drug use and HIV transmission ultimately affect all members of soci-
ety. In countries with injecting drug use related HIV epidemics, HIV infection rates amongst IDUs,
who have shared injecting equipment or had unprotected penetrative sexual intercourse, have risen
and continue to rise sharply. In fact, in some parts of the world, injecting drug use has kick started
the HIV epidemic. This was the case in Thailand, where during the first nine months of 1988, HIV
prevalence rates among IDUs in Bangkok rose from around zero to almost 40 per cent. Before that,
there were few people known to have HIV in Thailand. Afterwards HIV prevalence rates increased
dramatically, mainly through sex.21
This means that countries with little HIV infection but with IDUs can go from few people infect-
ed to many thousands in a short space of time, forming an epicentre for further spread of HIV. IDUs
who are sexually active may transmit HIV to their sexual partners and their children. This situation
is compounded by the involvement of many IDUs in commercial sex work, often to support their
drug use. It is also compounded in prisons which mix many different IDU populations, and are also
a setting in which drug use and injecting drug use is frequently initiated. Experience has shown,
without effective immediate harm reduction programmes, IDU-based HIV epidemics can rapidly
become self-sustaining generalized HIV/AIDS epidemics.
Section 1.4 
The most affected populations
In general, injecting drug use is associated with pre-existing socio-economic deprivation. Due to the
amount of resources necessary to provide drugs, most injecting drug users live in poverty. Many
IDUs come from low-income households. When HIV infection leads to illness, this brings reduced
income from the person with HIV and often further economic and social costs associated with fam-
ilies caring for their relatives. This in turn leads to further poverty and increased likelihood of other
family members engaging in risky HIV behaviours.
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In addition, there are some populations particularly susceptible to injecting drug use and HIV infec-
tion. Female IDUs are at a higher risk of HIV infection mainly due to drug mixing or commercial
sex work 22, while injecting drug use is a severe problem among street youth.23 Migrants, because of
their proximity to drug cultivation or trafficking routes, or because of their general situation, are
often over represented in drug use.24 Existing data also indicate that indigenous people are often over
represented in groups most vulnerable to HIV, such as sex- workers and prisoners. In particular,
indigenous people are over represented among inner city IDU communities, including among clien-
tele using needle exchange programmes and counselling or referral sites.25
Injection drug use is also a problem among prisoners (a population whose welfare is specifically with-
in the mandate of the Movement and an area in which the Red Cross and Red Crescent has a com-
parative advantage). Once in prison, many IDUs continue injecting and prisons are also a setting
where many people have their first experience of using or injecting drugs.26 Sex, forced or consensu-
al, is common in prison and is generally unprotected. Another often forgotten aspect of prison life
is the past time of tattooing using needles.
In many countries, current prison practices effectively promote the transmission of HIV and tuber-
culosis (TB) infections within prisons and thereafter into the general community upon prisoner
release. Few countries have implemented harm reduction measures in prisons. The main reasons
given are that sex and drug use is illegal and that needles and condoms may be used as weapons.
Europe leading the way on needle and 
syringe exchange programmes in prisons
Needle and syringe exchange programmes are still rare but on the increase. Since the first prison-
based syringe exchange programme was set up at the Oberschöngrun prison for men in
Switzerland in 1992, studies of similar programmes have confirmed their effectiveness.
Needle sharing has declined dramatically, there have been no reported cases of inmates acquiring
HIV, HBV or HCV in any of the programmes, and no serious unintended consequences were
encountered. By 2001, sterile needles were being distributed in seven Swiss prisons.27
German and Spanish authorities have also successfully introduced needle exchange schemes in
several prisons. HIV prevalence among Spanish prisoners has declined from 23 per cent in 1996
to 17 per cent in 2001, due largely to innovative programmes for heroin users (methadone pro-
grammes). Nine of the country’s prisons have begun introducing needle and syringe exchange
programmes complemented by education, counselling and condom distribution.28
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21 Drug Use and HIV/AIDS, UNAIDS statement presented at the United Nations General Assembly Special Session on Drugs, 9 June 1999.
22 Spittal PM, Craib KJ, Wood E, Laliberte N, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT, Risk factors for elevated HIV incidence rates among female injecting drug
users in Vancouver, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, 166(7) pp. 894-9, CMAJ, 2 April 2002. Barnard M, Risky Business,
43 The International Journal of Drug Policy, 1993. HIV/AIDS Among Injecting Drug Users in Canada, Health Canada, April 2003.
23 For example, one study found that one-third of a sample of Montréal street youth had injected drugs in the previous six months. Among those who were regular injectors, 47
percent had shared needles in this time frame Risk Behaviours Among Injection Drug Users in Canada, supra, note 1 at 3, with reference to E Roy, N Haley, J Boivin et al.
Injection Drug Use among Street Youth: A Dynamic Process. Paper presented at the 6th Annual Conference on HIV/AIDS Research, Ottawa, May 1997. Canadian Journal of
Infectious Diseases 1997; 8 (Suppl A): 29A (abstract 225).
24 Stimson GV, Adelekan M, Rhodes T, The Diffusion of Drug Injecting in Developing Countries, The Centre for Research on Drugs and Health Behaviour, University of London.
This article is based on a presentation at the Sixth International Conference on the Reduction of Drug Related Harm, Florence, Italy, 1995.
http://www.drugtext.org/library/articles/96745.htm.
25 Stimson GV, Adelekan M, Rhodes T, The Diffusion of Drug Injecting in Developing Countries, The Centre for Research on Drugs and Health Behaviour, University of London.
This article is based on a presentation at the Sixth International Conference on the Reduction of Drug Related Harm, Florence, Italy, 1995
http://www.drugtext.org/library/articles/96745.htm.
26 For example, in a federal prison in British Columbia, 67 percent of inmates responding to one survey reported injection drug use either in prison or outside, with 17 percent reporting
drug use only in prison. T Nichol. Bleach Pilot Project. Second unpublished account of the introduction of bleach at Matsqui Institution, dated 28 March 1996. On file with Legal
Network. In the 1995 inmate survey conducted by the Correctional Service of Canada, 11 percent of 4285 federal inmates self-reported having injected since arriving in their current
institution. Correctional Service of Canada. 1995 National Inmate Survey: Final Report. Ottawa: The Service (Correctional Research and Development), No SR-02 at 138, 1996.
27 Report on the Global HIV/AIDS Epidemic, p 98, UNAIDS, July 2002.
28 Report on the Global HIV/AIDS Epidemic, p 98, UNAIDS, July 2002.
Generally, refugees and people involved in conflict situations are at an increased risk of HIV/AIDS.
In the turmoil that leads people to become refugees, health-care information and related services for
HIV prevention usually do not exist. However, injecting drugs by IDUs before an emergency is like-
ly to continue. Given the circumstances, if drugs are available, this is likely to increase.
Unfortunately, injecting drug use in emergency settings is little understood.
Section 1.5
Effective responses
Emerging evidence with regard to successful approaches has demonstrated that HIV transmission
among IDUs can be prevented. There are three complementary strategies:
■ Decrease the social marginalization and the subsequent vulnerability of IDUs.
■ Increase the access of IDUs to health and social care, including drug education, comprehensive
package of interventions for HIV prevention and treatment services.
■ Promote a non-repressive approach to IDUs based on human rights and public health 
principles. 29
In spite of existing proven strategies for curbing the transmission
of HIV related to injecting drug use, most countries to date have
failed to introduce comprehensive harm reduction programmes.
Since the first needle exchange programme (NEP) was introduced
in Amsterdam in 1984, at least 46 regions, countries, and territo-
ries reported having at least one NEP by December 2000.
However, only one-third of countries where HIV has been report-
ed among IDUs, and only 40 per cent of countries where injecting
drug use is known to occur, have introduced at least one NEP. 30
Furthermore, there are also no cases globally of transmission of
HIV or hepatitis as a result of a needle-stick injury from an inap-
propriately discarded needle and syringe. 31
The failure to introduce effective HIV prevention measures such as comprehensive harm reduction
programmes for IDUs costs lives. For example, it is estimated that for each year without increased
access to sterile syringes for IDUs, as many as 12,350 persons in the United States are becoming
infected with HIV. 32
Some of the reasons for the lack of an effective response include:
■ marginalization and stigmatization and discrimination against injecting drug users;
■ antipathy towards public health approaches to reducing the individual and social costs of drug use;
■ lack of political will to develop the necessary policy dialogue and programmatic response;
■ drug use viewed as a criminal rather than a public health issue;
■ failure to recognize injecting drug use as a factor in the HIV epidemic;
■ denial of international evidence on effective responses;
■ failure to address the legal, ethical and human rights issues concerning IDUs;
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29 Preventing the Transmission of HIV among Drug Abusers, position paper of the United Nations System, 2000.
30 Steffanie A. Strathdee and David Vlahov The effectiveness of needle exchange programs: A review of the science and policy, Vol. 1, No. 16, AIDScience, December 2001.
31 Dolan, K., Topp, L. and MacDonald, M., NSP: needle and syringe programs: a review of the evidence. In NSP: Needle and Syringe Programs [Information kit], Canberra:
Australian National Council on AIDS, Hepatitis C and Related Diseases, p. 18, 2000.
32 Holtgrave, David R., Pinkerton, Steven D., Jones, T. Stephen, Lurie, Peter., and Vlahov, David., 1998, Cost and cost-effectiveness of increasing access to sterile syringes and needles
as an HIV prevention intervention in the United States, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18 (supplement), pp. S133-S138.
33 Steffanie A. Strathdee and David Vlahov The effectiveness of needle exchange programs: A review of the science and policy, Vol. 1, No. 16, AIDScience, December 2001.
Strathdee, S. A. et al., Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. 11, F59-F65, AIDS, 1997.
34 Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, Schechter MT, Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidem-
ic, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada, 17(6):911-3, AIDS, 11 April 2003. 
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■ lack of easily accessible, quality treatment service;
■ insufficient understanding of the impact of HIV on society;
■ poor networking and integration between sectors and agencies responsible for drug control and
HIV prevention; and
■ limited skills, resources (both human and financial) and experience in understanding and
responding to IDUs and HIV.
To be effective, harm reduction programmes must fit local conditions. For example, research in
Canada has shown that cocaine injectors tend to inject much more frequently than heroin injectors,
and therefore require much greater quantities of needles and syringes than usually provided by nee-
dle-syringe programmes.33 In addition, the time to HIV infection was accelerated among regular
cocaine injectors independent of concurrent heroin use. Injecting cocaine use was a strong, dose-
dependent predictor of HIV seroconversion in this poly-drug using population. Injecting cocaine
users remain particularly vulnerable to HIV infection and while treatment options for cocaine
dependency remain woefully inadequate.34
Harm reduction programmes that only reach a minority of injecting drug users may yield benefits
for those participating but are unlikely to significantly influence the course of the HIV epidemic in
a country. For example, Nepal introduced needle exchange programmes in 1991. By 1995, some
researchers were claiming that the interventions had averted an HIV epidemic among injecting drug
users. But by 1997, almost half the users tested in Kathmandu were infected with HIV. The needle
exchange programme was too limited and too localized to have a powerful, lasting impact.
Appropriate coverage of all injecting drug users is an important target for national HIV/AIDS pro-
gramming. To be effective, it needs to include IDUs involved in sex work, living in prisons, from
ethnic minorities, migrants and refugees.
17Spreading the light of science
A
nd
re
w
 M
ac
C
ol
l/
Fe
de
ra
tio
n
Section 2.1 
Harm reduction
In public health harm reduction is used to describe a concept aimed at preventing or reducing neg-
ative health consequences associated with certain behaviours. In relation to HIV and injecting drug
use, harm reduction aims at preventing the transmission of HIV and other infections that occur
through sharing of non-sterile injecting equipment and drug preparations.35/36  Harm reduction takes
a morally neutral stance to drug use, neither condoning nor opposing drug use. It focuses on actual
harm and assumes that some people will continue to use injecting drugs despite government repres-
sion and therefore they should be given the possibility to do so in an in a way that reduces the risks
and causes least harm to themselves and others.
While many governments, organizations and individuals would like to see drug free societies, the role
of harm reduction is not to work directly towards this. If individuals who inject drugs go into rehabil-
itation programmes as a result of contacts made through harm reduction programmes, this is a welcome
spin off effect but it is not an aim of harm reduction strategies. Demand reduction is a separate strate-
gy which seeks to reduce the use of drugs. Harm reduction acknowledges drug use without condoning
it, and seeks to minimize the harm to the individual and by correlation to the society as a whole.
A hierarchy of objectives for harm reduction has been put forward:
■ Enter into drug dependence treatment. Those offering long-term medications such as
methadone maintenance are more effective. 
■ If drug dependence treatment is not an option switch from injecting to non-injecting drug use. 
■ If injecting continues always use sterile injecting equipment and do not share equipment or
drug solutions. 
■ If it is not possible to use sterile injecting equipment clean and reuse your own equipment and
do not share it. 
■ If sharing does occur, clean injecting equipment between each use (using bleach, for example). 
■ Do not share ‘cookers’, drug containers or filters used for injecting, and do not use or share
water for rinsing or mixing. 
■ Avoid unprotected sex. Always use condoms.37
Harm reduction can consist of various measures including: 
■ needle and syringe exchange programmes; 
■ the provision of condoms;
■ medical treatment using opiate substitutes;
■ psycho-social counselling; and 
■ strategies for reaching out to the most vulnerable populations and those with no access to
health care systems. 
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35 Injecting Drug Use and HIV/AIDS: World AIDS Campaign, UNAIDS, 2001.
36 Harm reduction encompasses a wide range of drug user services including needle and syringe exchange, injecting drug rooms, drug substitution, health education, medical
referral and support services.
37 Pecheny, Mario, Argentina: Discrimination and AIDS Prevention, in Peddro: Drug Abuse and AIDS – stemming the epidemic, UNESCO, European Commission and
UNAIDS, Special Issue, December 2001.
HIV education; voluntary and confidential testing for HIV
infection; and adequate pre- and post-test counselling and
treatment for HIV infection, including ARV treatments,
should all be considered as other interventions which can
mitigate the impact of HIV/AIDS on individuals and
communities. The creation of safe injecting environments
with medical backup as well as the decriminalization of
drug use are both strategies that have been successfully
introduced to minimize drug related harm.
In many countries injecting drug users are marginalized,
stigmatized and discriminated members of the society.
Many states have taken punitive measures against IDUs
with the objective of preventing illegal drug use, but with
little success. International conventions, declarations and
humanitarian principles obligate states to respect, protect
and fulfil, equitably and in a non-discriminatory manner,
IDUs’ human rights, which includes comprehensive harm
reduction programmes as well as providing treatment, care
and support, including anti-retroviral therapy for HIV-
positive IDUs, if medically recommended. 
In addition, public health imperatives support the introduction of comprehensive harm reduction
programmes as a proven way to protect public and individual health. Furthermore, scientific evi-
dence shows that harm reduction strategies including needle and syringe exchange are cost-effective
measure to prevent and control HIV transmission, do not lead to higher rates of drug use and pro-
tect the individual’s right to health.
Section 2.2 
Humanitarian rationale
2.2.1 Humanitarian action, National Societies 
and injecting drug users
Most IDUs are at a high risk of contracting HIV/AIDS, HBV, HCV and other infections. They
often suffer stigma and discrimination and face high levels of incarceration. IDUs are vulnerable
groups that require Red Cross and Red Crescent support. Too often, the issues of drug use, HIV
transmission and harm reduction methods are entangled in political, religious and moral debates to
the detriment of prevention and care efforts.
The Red Cross and Red Crescent, as the largest and oldest humanitarian organization established
with the objectives of preventing and alleviating human suffering without judgement wherever it
may be found, can take an active role in education. It can ensure a clear understanding of the scale
of the HIV/AIDS epidemic, and advocate for appropriate and effective prevention, treatment, care
and support measures. Of the seven Fundamental Principles of the International Red Cross and Red
Crescent Movement, three – humanity, impartiality and neutrality – are particularly important for
prevention and for rendering treatment, care and support to IDUs.
At the Governing Board meeting held in November 2002, The International Federation adopted a
new HIV/AIDS Policy, which states
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“guided by sound public health and humanitarian principles, promote and where appropriate facil-
itate harm reduction strategies for high risk behaviours and traditional practices, including advoca-
cy for law reform as necessary.”
In April 2002, the European National Societies Conference in Berlin unanimously supported imple-
menting harm reduction strategies, marking a major step forward to addressing the rapid increase in
infection in the region. Similarly, the Manila Action Plan, adopted at the Manila Conference in
December 2002, requires all National Societies in the Asia, Pacific and Middle East regions to devel-
op culturally appropriate harm reduction programmes.
Several National Red Cross and Red Crescent Societies have already initiated harm reduction strate-
gies in collaboration with governments or other organizations. The Australian, Croatian, Italian,
Portuguese, Russian and Spanish National Societies are demonstrating workable programmes. The
Vietnamese and Chinese Red Cross Societies also have initiatives underway. Many National Red
Cross and Red Crescent Societies have capacities and networks which can be utilized to support
IDUs and advocate for the acceptance, introduction and maintenance of harm reduction pro-
grammes.
2.2.2 Humanitarian action, National Societies 
and injecting drug users in prisons
According to the fundamental principle of humanity, the Red Cross and Red Crescent “endeavours,
in its international and national capacity, to prevent and alleviate human suffering wherever it may
be found”. Its purpose is to protect life and health and to ensure respect for the human being. 
The role of National Societies has grown from serving as
auxiliaries to an army’s medical services in times of war,
to include welfare activities38 developed in favour of fam-
ilies and children, the elderly, sick people and people
with disabilities (mental, physical and social disadvan-
taged) in times of peace. The last of these groups includes
detainees.
In its efforts to implement the principle of humanity, the
Red Cross and Red Crescent pays particular attention to
the most vulnerable people. The Red Cross and Red
Crescent philosophy and doctrine and its fundamental
principles provide basic guidelines for the social welfare
work of National Societies in favour of prisoners and
their families. The reasons for National Society activity
in prisons are individual assistance to the prisoners as
human beings; help and assistance to their families; and
to assist as much as possible during the period of separa-
tion from normal conditions of life.
National Societies are auxiliaries to the public authorities
and must maintain their independence, impartiality
(non-discrimination) and autonomy in relation to states,
and must be neutral and impartial. That is they must be
non-discriminatory as to nationality, race, religious
beliefs, class or political opinion; and proportional in the
manner in which assistance to prisoners is distributed. 
International Federation of Red Cross and Red Crescent Societies20
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National Societies cannot take the place of the state, which has the task of providing assistance to
underprivileged individuals since they are the only entity with the necessary authority and sufficient
resources to cope with an undertaking of this magnitude. 
The provision of health services is the most common activity of National Societies work in prisons.
Some National Societies provide care, medicine and other services to sick persons. A few National
Societies are providing assistance to drug dependants. Some organize courses such as first-aid train-
ing or seminars on HIV/AIDS for health personal and/or prisoners. Some National Societies also
provide medical care to family members of prisoners, cover medical costs or conduct campaigns
against particular diseases.
There is ample scope for National Societies to build on existing activities in prisons to provide
HIV/AIDS related services. National Societies can advocate with governments, prison services and
wardens for the acceptance, introduction and maintenance of harm reduction programmes. And giv-
ing due regard to its auxiliary role, National Societies may be in the position to facilitate harm reduc-
tion measures in prisons.
At the request of National Societies or on its own initiative, the
International Federation secretariat can contribute to the activities of
National Societies by providing guidance in social welfare, including
health service provision and harm reduction measures for IDUs in pris-
ons. The International Federation can also provide information on the
activities of the National Societies and promote cooperation and
exchange of experience. National Societies requiring background infor-
mation on mandates for work in prisons are referred to the publication
Activities of National Red Cross and Red Crescent Societies in Prisons
(International Federation and Henry Dunant Institute, 1994).39
Section 2.3 
Public health rationale
The sharing of needle and syringes and other drug injecting equipment is the most important fac-
tor fuelling the HIV epidemic among drug users. Drug control laws and policies should aim to
reduce, not increase, the HIV risk faced by injecting drug users. Popular strategies of suppression or
elimination have not contained the fast growth of HIV epidemics. Experience has shown that HIV
epidemics among IDUs can be halted, or if IDUs are appropriately supported through a compre-
hensive harm reduction approach at an early stage, epidemics can be minimized or avoided.
A global review of needle and syringe exchange programmes implemented between 1993 and 1998 in
29 cities has shown that the HIV prevalence rate among IDUs decreased by an average of 58 per cent
per year while the number of users did not increase. By contrast, in 52 cities, where similar harm reduc-
tion programmes did not exist, the HIV prevalence rate increased by almost 6 per cent annually.40
Effective public health interventions to limit the transmission of HIV are required for several reasons:
■ Currently, it is estimated that there are more than 10 million people globally who inject drugs.
Of these, 2-3 million people are estimated to be HIV-positive.
■ The number of countries reporting injecting drug use has increased from 80 in 1992 to 138 in
1998 with 114 countries reporting HIV infection among the IDU population.
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38 Social welfare, material assistance, health services, organization and arrangements relating to work in and outside prisons, training, education, entertainment, leisure, sport,
special care for young prisoners and children of prisoners, facilitation of contacts by foreign prisoners with their country and families, intervention in favour of nationals
imprisoned abroad, development of alternative measures to imprisonment and social rehabilitation and reintegration.
39 To order, e-mail guidera@ifrc.org.
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■ The reuse of contaminated needles and syringes by different people as well as the communal
use of equipment for injecting preparation are common practices among IDUs.
■ HIV and other blood borne infections are efficiently transmitted by sharing injecting 
equipment.
■ HIV can rapidly spread through drug using populations and can stabilize at high prevalence
rates. Studies indicate that in the absence of preventive measures the prevalence rate can rise up
to 40 per cent or more within 1-2 years of introduction of HIV into a community. 
■ Transmission of HIV also occurs through sexual contact both between IDUs and with other
sexual partners, including through sex work, facilitating the transmission of HIV to their chil-
dren and into the general community.
Section 2.4 
Human rights rationale
2.4.1 Human rights, health and injecting drug users
The right to health is enshrined in international human rights law, even if these rights do not appear
under the explicit title of ‘the right to health’. Although subject to progressive realization and
resource constraints, this right imposes certain obligations. These immediate obligations include the
guarantees of non-discrimination and equal treatment, as well as the obligation to take deliberate,
concrete and targeted steps towards the full realization of the right of everyone to the enjoyment of
the highest attainable standard of physical and mental health. This might include the preparation of
a national public health strategy and plan of action. Progressive realization means that states have a
specific and continuing obligation to move as expeditiously and effectively as possible towards the
full realization of the right.
The preamble of the Constitution of the World Health Organization states, 
Health is a state of complete physical, mental and social well-being and not merely the
absence of disease or infirmity. The enjoyment of the highest attainable standard of health is
one of the fundamental rights of every human being without distinction of race, religion,
political belief, economic or social condition. The health of all peoples is fundamental to the
attainment of peace and security and is dependent upon the fullest co-operation of individu-
als and States. The achievement of any State in the promotion and protection of health is of
value to all… Governments have a responsibility for the health of their peoples which can be
fulfilled only by the provision of adequate health and social measures.41/42
The right of everyone to the enjoyment of the highest attainable standard of physical and mental
health, is reflected in Article 25(1) of the 1948 Universal Declaration of Human Rights; 43 Article 12
of the 1966 International Covenant on Economic, Social and Cultural Rights; 44 Article 24 of the
1989 Convention on the Rights of the Child;45 and Article 12 of the 1981 Convention on the
Elimination of All Forms of Discrimination against Women 46. 
The right to non-discrimination is enshrined in Article 5(e)(iv) of the 1965 International
Convention on the Elimination of All Forms of Racial Discrimination.47 The guarantees of non-dis-
crimination and equal treatment in the fulfilment of human rights means that everyone has the right
to the enjoyment of the highest attainable standard of physical and mental health. This by defini-
tion applies to people who inject drugs, including HIV-positive IDUs. 
The interpretation of existing human rights treaties confirms this. The resolutions passed by the UN
Commission on Human Rights in 1999, 2001 and 2003, invited UN bodies, international organi-
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zations and NGOs to take all necessary steps to ensure the respect, protection and fulfilment of
HIV-related rights.48
In May 2000, the UN Committee on Economic, Social and Cultural Rights adopted a general com-
ment on the right to health which proscribes,
any discrimination in access to health care and the underlying determinants of health, as well
as to means and entitlements for their procurement, on the grounds of race, colour, sex, lan-
guage, religion, political or other opinion, national or social origin, property, birth, physical
or mental disability, health status (including HIV/AIDS), sexual orientation, civil, political,
social or other status, which has the intention or effect of nullifying or impairing the equal
enjoyment or exercise of the right to health.49
In the Declaration of Commitment, unanimously accepted at the 26th UN General Assembly
Special Session on HIV/AIDS, 2001, states made specific commitments relevant to IDUs.
By 2005, ensure that a wide range of prevention programmes which take account of local cir-
cumstances, ethics and cultural values, is available in all countries, particularly the most affect-
ed countries, including...expanded access to essential commodities, including male and female
condoms and sterile injecting equipment. 50
By 2003...to promote and protect the health of those identifiable groups which currently have
high or increasing rates of HIV infection or which public health information indicates are at
greatest risk of and most vulnerable to new infection as indicated by such factors as the local
history of the epidemic, poverty, sexual practices, drug-using behaviour, livelihood, institu-
tional location, disrupted social structures and population movements, forced or otherwise. 51
By 2003, all States will have eliminated any laws, policies and practices that discriminate
against people living with HIV/AIDS and other highly vulnerable groups. 52
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41 The Constitution of the World Health Organization was adopted by the International Health Conference held in New York from 19 June to 22 July 1946, signed on 22
July 1946 by the representatives of 61 states http://www.who.int/governance/en/.
42 Governments have made commitments to ensuring progressive realization of the Human Right to Health at nearly every major Conference during the past decades including:
■ Ottawa Charter for Health Promotion, First International Conference on Health Promotion, Ottawa, 21 November 1986 - WHO/HPR/HEP/95.1
http://www.who.int/hpr/NPH/docs/ottawa_charter_hp.pdf
■ Cairo Programme of Action, Principle 8 and para. 8.6, International Conference on Population and Development, Cairo, 5-13 September 1994.
http://www.iisd.ca/linkages/Cairo/program/p00000.html
■ Habitat Agenda, paras. 36 and 128, United Nations Conference on Human Settlements (Habitat II), Istanbul, Turkey, 3 - 14 June 1996.
http://www.unhabitat.org/unchs/english/hagenda/ist-dec.htm
■ Copenhagen Declaration, Commitment 6, World Summit for Social Development, Copenhagen, Denmark 14-15 October 1999.
http://www.un.org/esa/socdev/wssd/agreements/
During its session in May 1998, the World Health Assembly endorsed the new World Health Declaration and the new global health policy Health for All in the 21st
Century. Health for All in the 21st Century guides action and policy for health at all levels and identifies global priorities and targets for the first two decades of the 21st
century. Key values such as human rights, equity, ethics and gender sensitivity should underpin and be incorporated in all aspects of health policy. A key feature is the
strengthening of the participation of people and communities in decision- making and actions for health.
Important global "health for all" targets by 2020 include: "... the worldwide burden of disease will be substantially decreased. This will be achieved by implementation of
sound disease-control programmes aimed at reversing the current trend of increased incidence and disability caused by tuberculosis, HIV/AIDS, ...all countries will have
introduced, and be actively managing and monitoring, strategies that strengthen health-enhancing lifestyles and weaken health-damaging ones, through a combination of
regulatory, economic, educational, organizational and community-based programmes".
43 Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, including food, clothing, housing and medical care and necessary
social services, and the right to security in the event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances beyond his control.
44 The States Parties to the present Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.
45 States Parties recognize the right of the child to the enjoyment of the highest attainable standard of health and to facilities for the treatment of illness and rehabilitation of
health. States Parties shall strive to ensure that no child is deprived of his or her right of access to such health care services.
46 States Parties shall take all appropriate measures to eliminate discrimination against women in the field of health care in order to ensure, on a basis of equality of men and
women, access to health care services, including those related to family planning.
47 In compliance with the fundamental obligations laid down in article 2 of this Convention, States Parties undertake to prohibit and to eliminate racial discrimination in all
its forms and to guarantee the right of everyone, without distinction as to race, colour, or national or ethnic origin, to equality before the law, notably in the enjoyment of
the following rights: Economic, social and cultural rights, in particular: The right to public health, medical care, social security and social services.
48 1999/49 of 27 April 1999; 2001/51 of 24 April 2001 and 2003/L.64 of 16 April 2003. http://www.unhchr.ch/html/menu2/2/sessions.htm.
49 General Comment 14, Paragraph 18. http://www.unhchr.ch/tbs/doc.nsf/(symbol)/E.C.12.2000.4,+CESCR+General+comment+14.En?OpenDocument.
50 UNGASS, Paragraph 52 http://www.unaids.org/UNGASS/.
51 UNGASS, Paragraph 64 http://www.unaids.org/UNGASS/.
52 UNGASS, Paragraph 58 http://www.unaids.org/UNGASS/.
The above outlines the legal basis for states to respect, protect and fulfil, equitably and in a non-dis-
criminatory manner all IDUs’ human rights. This includes comprehensive harm reduction pro-
grammes as well as providing treatment, care and support, including anti-retroviral therapy for HIV-
positive IDUs, if medically recommended.
In keeping with the fundamental principles and the role of the Red Cross and Red Crescent in pro-
tecting and promoting the health of the most vulnerable populations, IDUs as a vulnerable popula-
tion merit the strong and privileged voice of social conscience. The International Federation can
advocate governments to fulfil IDUs’ right to the enjoyment of the highest attainable standard of
physical and mental health.
2.4.2 Human rights, health and injecting drug users in prisons
As with all HIV infection of IDUs, HIV transmission between IDUs in prisons is largely preventa-
ble. Furthermore, the principal international human rights documents clearly obligate states to pro-
tect the human rights of prisoners.
Article 7 of the International Covenant on Civil and Political Rights (ICCPR) and Article 16 of the
Convention Against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment
(CAT) both prohibit torture and cruel, inhuman, or degrading treatment or punishment, without
exception or derogation. 
Furthermore, Article 10 of the ICCPR mandates that “all persons deprived of their liberty shall be
treated with humanity and with respect for the inherent dignity of the human person”. It also
requires that the reform and social readaptation of prisoners be an essential aim of imprisonment.
Finally, Articles 2 and 26 of the ICCPR contain, respectively,  provisions concerning the discrimi-
natory application of the convention and a general right to equality.
Other UN standards applicable to the treatment of prisoners include:
■ United Nations Standard Minimum Rules for the Treatment of Prisoners, 1957; 
■ Body of Principles for the Protection of All Persons Under Any Form of Detention or
Imprisonment, 1958; 
■ Basic Principles for the Treatment of Prisoners, 1990; 
■ Code of Conduct for Law Enforcement Officials, 1978; and 
■ Principles of Medical Ethics Relevant to the Role of Health Personnel, Particularly Physicians,
in the Protection of Prisoners and Detainees against Torture and Other Cruel, Inhuman or
Degrading Treatment or Punishment, 1982. 
With regard to juvenile prisoners applicable UN standards include:
■ United Nations Standard Minimum Rules for the Administration of Juvenile Justice, 1985;
■ United Nations Guidelines for the Prevention of Juvenile Delinquency, 1990; and
■ United Nations Rules for the Protection of Juveniles Deprived of Their Liberty, 1990. 
Also applicable is the 1990 United Nations Standard Minimum Rules for Non-custodial Measures.
All these instruments are binding on governments to the extent that the norms set out in them expli-
cate the broader standards contained in human rights treaties.53 They clearly reaffirm the tenet that
prisoners retain their fundamental human rights. 
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53 For texts, see http://www.unhchr.ch/html/intlinst.htm.
54 Principle 5, Basic Principles for the Treatment of Prisoners, Adopted and proclaimed by General Assembly resolution 45/111 of 14 December 1990.
55 United Nations Human Rights Committee, General Comment 21, Paragraph 3, 1992. The Human Rights Committee provides authoritative interpretations of the
ICCPR though the periodic issuance of General Comments.
56 Ibid., paragraph 4; see also Mukong v. Cameroon (No. 458/1991) (August 10, 1994), UN Doc. CCPR/C/51/D/458/1991 (stating that minimum requirements regarding floor
space, sanitary facilities, provision of food, etc., must be observed, “even if economic or budgetary considerations may make compliance with these obligations difficult”).
The most recent of these documents, the Basic Principles for the Treatment of Prisoners declares, 
except for those limitations that are demonstrably necessitated by the fact of incarceration, all
prisoners shall retain the human rights and fundamental freedoms set out in the Universal
Declaration of Human Rights, and, where the State concerned is a party, the International
Covenant on Economic, Social and Cultural Rights, and the International Covenant on Civil
and Political Rights and the Optional Protocol thereto, as well as such other rights as are set
out in other United Nations covenants. 54
Endorsing this philosophy in 1992, the UN Human Rights Committee explained that states have “a
positive obligation toward persons who are particularly vulnerable because of their status as persons
deprived of liberty” and states,
not only may persons deprived of their liberty not be subjected to [torture or other cruel,
inhuman or degrading treatment or punishment], including medical or scientific experimen-
tation, but neither may they be subjected to any hardship or constraint other than that result-
ing from the deprivation of liberty; respect for the dignity of such persons must be guaran-
teed under the same conditions as for that of free persons. Persons deprived of their liberty
enjoy all the rights set forth in the [ICCPR], subject to the restrictions that are unavoidable
in a closed environment. 55
Significantly, the UN Human Rights Committee has also stressed that the obligation to treat persons
deprived of their liberty with dignity and humanity is a fundamental and universally applicable rule,
not dependent on the material resources available to the state party. 56
One significant consequence of this framework is that the enjoyment of the highest attainable standard
of health is applicable to every human being without distinction as to race, religion, political belief,
and economic or social condition. Therefore it applies equally to prisoners and detained persons. 
As such, the lack of HIV education; harm reduction measures and voluntary and confidential testing
for HIV infection; adequate pre- and post-test counselling and treatment for HIV-infected prisoners;
as well as mandatory HIV testing and segregation of HIV-positive prisoners, undermine the public
health response to HIV/AIDS, are contrary to human rights and compromises the human dignity of
the person.
In addition, one measure of whether states are protecting the human rights of IDUs in prisons is
whether they are receiving the same prevention and care measures as IDUs in the general commu-
nity. For this to be a true measure, IDUs in the community must have access to comprehensive harm
reduction programmes. If they are HIV-positive, they must be receiving non-discriminatory access
to treatment, care and support, including anti-retroviral therapy, if medically indicated.
Section 2.5 
Cost effectiveness harm 
reduction programmes
An expanded and sustained implementation of comprehensive harm reduction programmes is effec-
tive in the prevention and control of the spread of HIV and other blood-borne infections. The
Australian National Council on Drugs (ANCD) conducted a study on harm reduction programmes
implemented in the ten years from 1990-2000. According to the findings, harm reduction pro-
grammes were successful:
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■ An estimated 25,000 cases of HIV infection were prevented.
■ An estimated 21,000 cases of HCV were prevented.
■ More than 5,000 lives are estimated to be saved up to the year 2010.
■ An investment of almost 150 million Australian dollars has resulted in an estimated return of
2.4-7.7 billion Australian dollars.57
In Svetlogorsk, Belarus, an HIV prevention programme included education about safe injecting and
safe sex, and provided clean syringes and condoms. In 1997, before the programme began, 92 per
cent of those surveyed said they shared syringes. By 1999, this percentage had dropped sharply to 35
per cent, while reported condom use doubled over the same period. 
The programme is estimated to have prevented over 2,000 cases of HIV infection by its second year,
at a cost of around US$ 68 per infection prevented; far below the cost of an AIDS case to a family
or a health system. The Belarus campaign was bolstered by a change in the law, which made it legal
to possess syringes and facilitated the funding and implementation of AIDS education and needle
exchange among drug users.58
Using data from Australia as a model, the number of HIV infections that could have been prevent-
ed by a national needle exchange programme in the United States from 1987-1995 were calculated.
Cost calculations were based on the US government estimate of the discounted lifetime cost of treat-
ing an HIV infection (US$ 55,640). It was calculated, conservatively, that the number of HIV infec-
tions that could have been prevented ranged from 4,394 (15 per cent incidence reduction due to
needle exchanges) to 9,666 (33 per cent incidence reduction). The
cost to the US health care system of treating these preventable HIV
infections is between US$ 244 million and US$ 538 million, respec-
tively.59
In 1995, it was estimated that an additional 5,150-11,329 preventa-
ble HIV infections could occur by the year 2000 if there was no
change in the policy on needle exchange programmes.60 Another study
estimated that for each year without increased access to sterile syringes
by injecting drug users, as many as 12,350 people in the United States
are becoming infected with HIV, leading to estimated cost of US$ 1.3
billion in future medical costs. This study concluded that it is three
times more expensive to provide medical treatment for one person ill
with HIV/AIDS than it is to prevent one new HIV infection using
needle exchange programmes and pharmacy sale of syringes.61
While governments often fear that programmes that facilitate IDUs access to clean needles and
syringes might result in more injecting drug use, the evidence does not support this view. Studies in
Australia, Canada, Sweden, the United Kingdom and the United States 62 have all shown that such
programmes – particularly in concert with other interventions – help reduce the sharing of injecting
equipment and the transmission of HIV. There was no evidence that they increased either the num-
ber of injectors or the frequency of injecting drug use.
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57 Australian National Council on Drugs, Needle and Syringe Programs, position paper, March 2002 http://www.ancd.org.au/publications/pdf/pp_needle_syringe.pdf.
58 Kumaranayake, L; Watts C, Vickerman, P; Walker, D; Zviagin V; Samoshkin S; Romantzov V., The cost-effectiveness of HIV preventive measures among injecting drug users in
Svetlogorsk, Belarus (draft), UNAIDS, May 2000 http://www.ahrn.net/pdf/Belarus.pdf.
59 David R. Holtgrave, Steven D. Pinkerton, T. Stephen Jones, Peter Lurie, and David Vlahov, 1998, Cost and cost-effectiveness of increasing access to sterile syringes and needles
as an HIV prevention intervention in the United States, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18 (supplement), pp. S133-S138.
60 Lurie P and Drucker E., An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA, Center for AIDS Prevention Studies,
University of California, San Francisco 94105, USA, Lancet. 1997 Mar 1; 349(9052):604-608.
61 David R. Holtgrave, Steven D. Pinkerton, T. Stephen Jones, Peter Lurie, and David Vlahov, 1998, Cost and cost-effectiveness of increasing access to sterile syringes and needles
as an HIV prevention intervention in the United States, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18 (supplement), pp. S133-S138.
62 In April 1998, the then US Secretary of Health and Human Services, Donna E. Shalala publicly announced that the scientific evidence proved needle exchange programs
were effective in preventing the spread of HIV and did not encourage the use of illegal drugs. U.S. Department of Health and Human Services, Research shows needle
exchange programs reduce HIV infections without increasing drug use, Press release, 20 April 1998.
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Section 3.1
Principles and strategy formulation
3.1.1 Guiding principles 
The social nature of drug injection, the complex dynamics of sharing injecting equipment, and the
interaction of drug use with high risk sexual behaviour, present considerable challenges for designing
effective responses.63 It is important to identify core principles underpinning appropriate responses.
The following are some of the major principles that National Societies intending to design harm
reduction programmes should consider.
Active involvement of injecting drug users: Developing useful responses to the problems
of HIV among IDUs is more likely to be effective if the views of people who inject drugs and the
local community are listened to and taken into account when developing responses.
Protection of human rights: People are more vulnerable to infections when their economic, health,
social and cultural rights are not respected. Respect for the rights of IDUs creates a favourable situation
for addressing the complexities of injecting drug use preventing the shqring of injecting equipment.
Early intervention: HIV prevention among IDUs should start as early as possible. Once HIV is
introduced into the community of IDUs the rate of transmission is fast.
Adequate coverage: It is recommended that at least 80 per cent of the target population is cov-
ered by comprehensive programming. Interventions should aim at achieving at least 60 per cent
change in risk behaviours.
Base line data: The development of programmes should be based on situation assessment to have
an in depth understanding of the local drug use pattern and the context. People outside IDU net-
works often know very little about the extent of the problem, nature of the subculture and the dif-
ferent determinants of the problem. Often prevailing social perceptions are not also well understood.
Such information gives useful insights for addressing challenges.
Humane and compassionate response: Drug abuse problems can not be solved simply by
criminal justice initiatives. Punitive action drives the people most in need of prevention and care
services underground.
Concerted effort: There is a need to develop cooperation at all levels.
Working modality: There is a need for developing service outside traditional settings. Outreach
work and peer education outside normal service settings, working hours and other conventional
working arrangements are needed to reach IDUs.
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63 National Societies requiring background information on how to design and carry out an assessment on HIV/AIDS and drug use are referred to the Aids Alliance 
publication Developing HIV/AIDS work with Drug Users – A Guide to Participatory Assessment and Response (August 2003). http://www.aidsalliance.org/
Chapter 3 
National Society response
3.1.2 Strategic directions 
It is useful to explain the difference between interventions and strategies. In these guidelines, interven-
tions comprise sets of activities and inputs required to achieve the desired outputs and outcomes. Strategy
is the method for implementing interventions in identified areas so as to achieve the desired impacts. 
In any given society, the prevailing social, political, cultural and economic conditions dictate the
selection of interventions for implementation. Strategy assists the realization of planned activities by
choosing appropriate interventions, which are supported by the necessary inputs to achieve the
planned outcomes to meet the set objective. Several key points need to be considered in the identi-
fication of strategies.
Availability of supportive national policy and legal basis: The strategy must be built
on a legal framework that can be adapted to allow comprehensive responses.
Awareness: Low level of awareness about the problem of drug use and HIV/AIDS, and inade-
quate knowledge about prevention leads to marginalization and stigmatization and discrimination
against IDUs. It is important to understand this when deciding on strategies.
Multi-sector approach: Strategies that encourage the establishment of broad based alliances of
local administration, police, health care providers, representatives of target population and commu-
nity-based organizations need to be considered.
Local responsibilities: Decision-making powers and allocation of funding are usually central-
ized. However, for effective impact these powers and resources must be delegated to the local level,
as appropriate.
Assessment: The identification of strategies must be based on baseline information concerning
IDUs and the social setting. The underlying conditions within the community, particularly the mag-
nitude, trend and dynamics of injecting drug use and the perceptions of the general community as
well as decision-making bodies must be taken into consideration in deciding on any given strategy.
Taking these considerations into account, National Societies should develop strategies which pro-
mote and where appropriate facilitate harm reduction strategies for injecting drug users including
advocacy for law reform, as necessary.
Section 3.2 
Programme development
As mentioned previously, the fundamental principles and mandate of the Movement obligate National
Red Cross and Red Crescent Societies to take all possible measures to assist injecting drug users.
Depending upon the prevailing conditions in any given country, National Societies can become
involved in programmes:
■ In countries where supportive policies exist, harm reduction programmes can be developed and
implemented.
■ In countries where supportive policies do not exist, National Societies can advocate with stake-
holders, decision-makers, community opinion leaders and the community at large for changes
in laws and policies related to injecting drug use to enable public health interventions.
■ In the absence of a supportive legal and policy framework, National Societies can negotiate
with governments to undertake pilot harm reduction programmes.
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Effective response requires concerted action in which key players are involved in the design of harm
reduction programmes. In developing such programmes, it is suggested to consider the several 
measures.
Active involvement of injecting
drug users: More than anyone else, IDUs
know well the nature of the problem they face
and the types of assistance relevant to them.
Therefore, efforts must be made to include
them in all phases of programme develop-
ment. Early contacts with IDUs are useful for
establishing relationships which can be
broadened through IDU involvement in pro-
gramme development and implementation.
Baseline data: In many countries and communities little is known about IDUs. Information
about IDUs, their social circumstances, their challenges, community perceptions and prevailing gov-
ernmental laws and policies need to be compiled, analysed and used as basis for programme devel-
opment – rapid situation assessment. Much of this information can be gleaned from IDUs if a rela-
tionship of trust is developed.
Community involvement: From the onset of programme development, all sectors of society,
including relevant individuals, families and the general community should be involved.
Involvement of professionals: Professionals with relevant backgrounds such as social, health,
law enforcement and criminal justice as well as International Organizations and NGOs should be
involved from the outset.
Pragmatic intervention: To be effective, interventions must be locally oriented and focussed on
the need of IDUs with provisions for periodic revision and adjustment when monitoring and eval-
uation of the programmes suggest that it is appropriate.
Integration: In many countries there are national drug control programmes which focus on
demand and supply reduction as well as national HIV/AIDS prevention and control programmes.
Harm reduction programmes should be linked to these national efforts.
Section 3.3 
Areas of intervention
In the last two decades, some countries have adopted different interventions for reducing risks
associated with injecting drug use. Based on the lessons learned, the following interventions have
been successful in reducing individual risk behaviour and preventing infection through sharing
injecting equipment:
■ outreach;
■ drop in centres;
■ needle and syringe exchange programmes;
■ provision of free, good quality condoms;
■ peer education;
■ primary health care provision;
■ drug substitution treatment; and
■ injecting drug rooms.
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3.3.1 Outreach
In many countries, drug use is illegal and drug users are prosecuted or may be harassed. IDUs can
be hard to reach and shun contact with authorities, including health services. In this situation, in
order to implement harm reduction programmes, it is necessary for outreach workers to go into the
IDU community and make contact in the settings where IDUs live or where they congregate such
as at train or bus stations, or in particular streets or parks.
Some features of outreach programme include:
■ Outreach workers establish themselves in localities where IDUs meet.
■ Establish face-to-face contact with IDUs. Such interaction helps create trust and facilitates
acquisition of information regarding the problems and needs of IDUs.
■ Provide services such as information on HIV/AIDS, first aid services, provision of condoms,
and clean needles and syringes or information on where these can be obtained.
■ Network with community groups in order to help integrate IDUs in social structures.
■ The people involved in outreach programmes must be given adequate training prior to 
moving into the IDU community.
■ Consider employing people who have experience working with IDUs to undertake outreach
work.
The above outreach methods
are most useful for reaching
the more visible IDU's, who
are often particularly vulnera-
ble. Consideration should
also be given to reaching the
larger number of IDU's who
are everywhere (such as recre-
ational drug users) and there-
fore more hidden and often
more difficult to identify and
reach. 
Secondary distribution: Croatia
The Croatian Red Cross has 105 well-structured branches with professional staff. Three syringe
exchange projects are being carried out in selected areas based on the number of IDUs. Activities
started in 1998 as part of the national strategy and include the distribution of needles and syringes
to IDUs, as well as the distribution of condoms and information material at needle exchange points. 
One of the main activities is secondary distribution. Clients at drug exchange points are used to 
further distribute syringes to other IDUs. It is estimated that there are 15,000-18,000 IDUs 
in Croatia. About 80 per cent of these are male and they are mainly heroine users. Most HIV 
transmission among IDUs is through unsafe sexual contacts.
3.3.2 Drop in centres
The situation in many countries is such that IDUs are often shunted from one place to the next. As
such many IDUs receive little or no governmental, social or family assistance. Drop in centres, some-
time known as boutiques, provide a safe space where IDUs can rest, shower, wash clothes, have light
refreshments and relax. For such centres to be effective, they must be non-judgemental and not pres-
sure clients.
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The services in the drop in centres can include:
■ showers;
■ shelter;
■ provision of washing machine service;
■ coffee and tea;
■ food;
■ first aid assistance for their health problems;
■ simple and understandable educational leaflets with contact information; and
■ someone to talk to.
Comprehensive harm reduction: Italy
Villa Maraini Foundation was founded in 1976. Of the
140 people working with the Foundation, 50 per cent are
ex-IDUs. The foundation has an emergency unit with a
help line, street unit, prison and shelter projects – both
drop in and for sleeping. The mobile teams operate with
the objectives of reducing overdose deaths and the
transmission of HIV/AIDS and other infectious diseases as
well as assisting IDUs outside of the rehabilitation centre
setting. The main tasks include:
■ syringe exchange at two locations in Rome;
■ distribution of condoms;
■ sharing information on drugs, prevention of
HIV/AIDS and other infectious diseases;
■ finding solutions for housing issues; and
■ psychological support.
3.3.3 Needle and syringe exchange programmes
Ensuring the availability of sterile injecting equipment so that each injection can be made free of
HIV contamination is a fundamental step in breaking the chain of transmission.
Needle and syringe programmes function on the bases of providing sterile needles and syringes
accompanied by educational materials, the provision of condoms as well as the collection of used
syringes and needles. It is important to ensure that used needles and syringes are disposed of safely. 
In many countries, sharp bins or containers are placed in toilets or other localities out of the view of
the general public. The inappropriate disposal of needles and syringes is often cited as a fundamen-
tal reason why communities reject needle and syringe exchange programmes.
Successful ways for increasing needle and syringe availability include:
■ sales of needle and syringes at minimum price through pharmacies
and other outlets;
■ free needle and syringe exchange programme; and
■ providing appropriate means for the disposal of used needles and
syringes.
Needle and syringe programme can be organized from:
■ fixed, user-friendly drop in centres;
■ self-help spaces;
■ through outreach workers;
■ through peer educators;
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■ mobile vans;
■ dispensing machines located at places easily accessible to IDUs; and
■ injecting drug rooms.
Where needle and syringe exchange programmes are not implemented because of legal or policy
restrictions, such as in prisons and detention centres, then bleach can be provided to clean used nee-
dles and syringes before reuse. However, such measures are not proven to reliably stop HIV trans-
mission and while better than nothing, must be considered as a compromise second line measure.
Taking every chance: harm reduction in Belarus
The Belarus Red Cross began harm reduction activities when the home care service was significantly
curtailed, leaving a large surplus of unutilized disposable syringes. In 2002, the local authorities
provided the Red Cross with the premises for a syringe exchange point. The Red Cross visited drug
abuse clinics and the police to discuss the importance of introducing harm reduction programmes
in light of the growing IDU-related HIV/AIDS epidemic. It also advertised its syringe exchange
activities through the local press. 
The Red Cross gained the trust of local IDUs and the programme has become popular. Every six
weeks sees around 60 syringes distributed by the Red Cross, while the municipal health authorities
were distributing the same amount of syringes during a whole year.
New for old: Latvia
Latvia has a population of 2.5 million people, 500,000 of whom live in the capital, Riga. HIV is
prevalent among the country’s youth. The Latvian Red Cross began syringe exchange activities in
Riga in 1997 and outreach work programmes in 1999. In 2002 the syringe exchange programmes
were expanded to eight municipalities and included the distribution of education material. 
In 2002, about 100-300 new clients were served every month; health education information was
updated regularly; and the rate of exchange of used syringes for new was close to 1:1. However, fund-
ing support for the programme has been difficult to maintain as the primary partner in Latvia
changed organizational priorities.
3.3.4 Provision of free, good quality condoms
Unprotected sexual contact between IDUs and with other non-drug injecting sexual partners is
another route for the transmission of HIV. Commercial sex work is often linked to drug use as it is
one way in which drug injecting can be financed. This creates the risk of HIV moving from the IDU
community into the general population via clients. Also, in prisons, sexual contact between inmates
is frequent and IDUs are disproportionately represented in prison populations.
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The provision of free, good quality condoms linked with education and information is a low cost
intervention which can prevent the sexual transmission of HIV. Condom distribution can be inte-
grated into many other interventions such as self-help spaces, outreach work, drop in centres, nee-
dle and syringe exchange programmes, peer education, primary health care provision, drug substi-
tution treatment and injecting drug rooms. They can also be provided by mobile vans and through
dispensing machines located in easily accessible places.
Central Asia
The reported number of HIV/AIDS cases in central Asia is progressively
increasing, mainly among IDUs, who account for 60-85 per cent of all new
infections. All five National Societies in central Asia are actively involved in
the distribution of high quality condoms and health information material to
targeted groups in the frame of their HIV/AIDS prevention programmes.
Current activities are mainly focused on youth peer education. The National
Society of Kazakhstan provides a hotline telephone service and anonymous,
free of charge, psychological support to different vulnerable groups.
From 2004, the National Societies of Kazakhstan and Uzbekistan plan to
involve IDUs and commercial sex workers in HIV/AIDS prevention activi-
ties. Home care for PLWHA is also planned.
3.3.5 Peer education
One of many reasons why people become involved in drug use is a lack of objective information con-
cerning the effects and risks associated with drug use. It is important to create environments where
relevant, objective information can be provided to drug users and to acknowledge that some people
do continue to take drugs when well informed, but are then more likely to manage the risks
involved. The use of trusted peer educators is an effective, proven method of reaching people who
use drugs in their own environment. 
Several features of peer education are worth noting:
■ Objective information can be provided to drug users and IDUs in their own environment.
■ Educational activities must take place in an environment of trust, which is best created by
information being provided by current drug users or IDUs, or ex-drug users or IDUs.
■ In the development and design of educational materials and approaches, drug users and IDUs
should be fully involved from the outset.
■ Printed educational materials can be used to provide information. However, it is acknowledged
that its effect on attitudes and behaviours is limited. Such materials should provide service
provider contact information.
Supporting injecting drug users: China
The Chinese government has registered more than one million drug users. The actual number of
drug users could be 3-8 million and is increasing, as the social and economic structures change faster
than many people’s ability to adjust. About one half of users inject and most share injection
equipment. This drives China’s HIV/AIDS epidemics. Nationally, 60 per cent of PLWHA are IDUs.
HIV infection rates among IDUs in some areas, particularly remote rural areas, are running at more
than 80 per cent.
Despite a 95 per cent relapse rate, government facilities that treat addiction continue to rely on ‘cold
turkey’ detoxification, physical rehabilitation through labour and rigorous physical exercise, and psy-
chological rehabilitation through self-criticism. Harm reduction measures, including methadone assist-
ed detoxification and substitution therapy, are new and implemented as small scale, pilot projects.
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The cultural imperative of familial responsibility, rather than individual rights, and society’s zero tol-
erance for drug use, ensure that IDUs are highly stigmatized. IDUs who have been through the gov-
ernment-run rehabilitation centres often express internalized shame and stigma.
Added to the stigma of weakness and degeneracy that attaches to drug users is the stigma of having
a (popularly perceived) self-inflicted and fatal illness. While many people in China are aware of
AIDS, few understand the routes of transmission and means of prevention. Many people who have
correct knowledge of HIV transmission often have incorrect beliefs about non-transmission, and
assume that casual contact or proximity to PLWHA can transmit the virus.
Efforts to provide care and support
The Sunshine Homeland for Drug Users in Kunming, Yunnan Province, developed and supported
by the Red Cross Society of China and the Australian Red Cross, incorporates peer education, home
care, and job skills
training to improve care
and support for former
drugs users and PLWHA.
Thirty recovering drug
users have been trained as
peer educators, and in the
first six months of the
project have facilitated 
23 workshops for 500
participants in drug
treatment centres and in
the community. 
Nineteen people have
attended a basic comput-
er skills course, and four-
teen have been trained in
first aid. Interviews with
project participants and their families indicate that the project is well-regarded and is, to date, attain-
ing the objectives of discouraging drug relapse, reducing stigma and discrimination by family and
communities towards those who have used drugs, as well as improving the self esteem of project par-
ticipants.
PE+ project in Yunnan and Xinjiang Provinces
PE+ is a Red Cross cooperative project. It is China’s first project to support the development of
PLWHA as educators and as people who have something to give to their communities. Almost all
PE+ educators are former drug users. PE+ trains PLWHA to educate their neighbours, friends, and
family about HIV/AIDS as well as caring for those who are infected. In contrast to other Red Cross
projects, PE+ is not structured and workshop-based, but relies on PE+ educators finding
spontaneous and natural opportunities to talk to others about HIV/AIDS, prevention, and care.
Weddings, funerals, mah-jong and card games, tea breaks during farm work – all are used as chances
for volunteers to distribute information and discuss HIV/AIDS. For more information, please send
an e-mail to <ifrccn12@ifrc.org>.
Involvement is a way forward: Viet Nam
For two years, a person with a history of drug use, who is also living with HIV, was supported by
the Red Cross of Viet Nam and the Australian Red Cross, to take the lead in outreach work to IDUs
and PLWHA and to bolster a community of support. Involvement in this work did much to repair
the self-esteem of this person who entered treatment voluntarily with support from his family.
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3.3.6 Primary health care services
Many IDUs do not have access to basic health care services or are afraid to use them even though
they may have been exposed to infections prevalent in their communities. IDUs are also susceptible
to health problems related to drug injections such as multiple abscess and skin lesions. 
In addition, many IDUs are without work and whatever money is available may be used for drugs.
As a result many IDUs suffer from malnutrition or are unable to pay for health care. Furthermore,
in terms of family background, IDUs may come from dysfunctional families or their addiction has
caused their family to cut from them; so that this traditional source of support is also not available.
Primary health care (PHC) services can address health problems including HIV infection.
HIV/AIDS related treatment and care aims to help drug users living with HIV/AIDS cope with the
infection. Involving IDUs living with HIV in primary health care and/or anti-retroviral treatment
programmes provides an opportunity for them to adopt and consolidate safe behaviours and may
yield significant HIV preventive effects, and most importantly can delay the on set of AIDS.
Prevention aspects apply particularly to HIV/AIDS treatment and care that is provided in the con-
text of specific information and counselling services.
The provision of information about PHC services and the services themselves can be integrated into
different harm reduction interventions including educational programmes and materials, self-help
spaces, drop in centres, injecting drug rooms, referral by outreach workers and mobile vans. Services
can also be provided through the coordination of referrals to health care institutions that provide free
medical care, by those working with IDUs.
Possible PHC services for IDUs:
■ medical care such as draining and dressing of abscesses and treatment of skin lesions;
■ treatment of common infections and sexually transmitted infections (STIs);
■ screening for TB and treatment;
■ provision of, or referral to, voluntary HIV testing and counselling services;
■ education on, and the provision of, basic materials to maintain personal hygiene;
■ education and the provision of materials to maintain sanitary conditions in the place of resi-
dence;
■ support, information and food for improving nutrition; and
■ vaccination programmes, particularly for HBV, for IDUs and their dependents.
Save a Mate: Australia
In Australia, the misuse of drugs is the sixth largest
killer of young people with up to 70 per cent of
overdoses witnessed, usually by a friend or family
member. The risk of a drug-related emergency is not
exclusive to any single age or socio-economic group
but traverses the whole of society. The prompt and
appropriate intervention by bystanders with the
provision of basic life support, cardio-pulmonary
resuscitation (CPR), before the arrival of ambulance
paramedics is an essential component in reducing
the number of deaths resulting from drug overdose.
Save a Mate (SAM) is an initiative of the New South
Wales branch of the Australian Red Cross. It is a
drug education programme and first-aid course
specifically designed for alcohol and other drug-
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related emergencies. The programme provides a general orientation to drug and alcohol issues, chal-
lenges myths, and teaches how to administer life-saving techniques in drug and alcohol emergencies.
SAM is targeted at people considered at most risk of engaging in harmful drug-taking behaviour, and
those who live or work in an environment where there is a risk of a drug and/or alcohol-related emer-
gency occurring.
The programme has two components:
1. Drug and alcohol seminar 
■ What is a drug?
■ Classes of drugs
■ Routes of administration and physiological dangers
■ Rationales behind drug use
■ Addiction, tolerance, overdose and harm in relation to drug use
2. First aid for drug-related emergencies
■ What is first aid?
■ Recognizing drug and alcohol emergencies and dealing with emergency assistance telephone
operators
■ Emergency action principles (DR. ABC)
■ Universal (standard) precautions
■ Legal considerations
■ Drug and alcohol first aid – CPR
Drug use affects everybody – the user, family members, children, and the wider community. If you
live or work with drug issues, the chances are you will encounter an overdose or drop at some point.
The skills taught in the SAM programme do save lives. In the event of overdose, people, profes-
sionals, friends or family, who are equipped with the knowledge and skills of first aid, which are
needed in the vital minutes before medical assistance arrives, can administer CPR – it can mean the
difference between life and death.
SAM has taken a traditional Red Cross service, first aid, and customized it to address a relevant con-
temporary issue, drug use. For more information, visit <www.nsw.redcross.org.au>.
3.3.7 Drug substitution treatment: low threshold programme
Some of the worst public health problems associated with drug use involve those drugs taken
through injection and where the injecting equipment is shared. Of all the modes of HIV transmis-
sion, directly injecting a substance including opiates such as heroin, methadone or morphine, or
other drugs such as cocaine, amphetamines, anabolic steroids, antibiotics or vitamins, contaminat-
ed with HIV into the blood stream is by far the most efficient.
In the case of heroin, IDUs can receive medically supervised treatment by drug substitution, which
does not give the same effects as the drugs themselves. Substitution drugs take care of the symptoms
of withdrawal and craving but do not provide a high. The benefit of substitution drugs is that phar-
macotherapy helps stabilize and normalize the lives of drug users. Methadone and buprenorphine
are the most commonly used substitution drugs, of which methadone is the best researched.
Some facts about methadone treatment and its uses: 64
■ Methadone is a synthetic opiate without strong sedative effects.
■ Methadone can be administered orally in tablet or syrup forms thus avoiding injections and the
possible associated risks of sharing needles and syringes and other injection paraphernalia.
■ Methadone can cause dependence of a lesser nature than that of other opiates.
■ People can stop using methadone by reducing the dose gradually.
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■ Retention of IDUs in substitution pro-
grammes reduces the health and social
consequences of drug use and eventual-
ly may lead to detoxification and absti-
nence.
■ For effective results, substitution drug
treatment must be combined with sup-
port for IDUs to reintegrate in society,
including employment, which requires
support in the work place.
3.3.8 Injecting drug rooms
Injecting drug rooms are still a controversial
harm reduction intervention, but there is lit-
tle doubt that such direct intervention saves
lives. The rooms are in effect, safe spaces for
injection with medical personal on hand to
provide first aid in the event of an overdose
or drop.
Section 3.4 
Facilitation of programme 
implementation
A coherent and smooth implementation of harm reduction programmes requires strong commit-
ment and concerted efforts of national and local policy-makers and public authorities. Moreover,
effective and broad-based community responses that involve NGOs, community-based organiza-
tions, IDUs and the private sector are also required.
National Red Cross and Red Crescent Societies have much experience in working within commu-
nities, with civil society, governments, and international donors and organizations in relief and devel-
opment related programmes. Harm reduction programmes have been proven to reduce the trans-
mission of HIV and other blood borne infections and increase the overall well-being of drug users
and injecting drug users. 
Yet the introduction and implementation of these programmes require additional efforts on the part
of National Societies, particularly in the field of advocacy. As such, programmes are often high pro-
file and require legal and policy reforms and changes. However, in keeping with the fundamental
principles of humanity, impartiality and neutrality, it is part of the Movement’s commitment to pro-
tect the most vulnerable without discrimination, which includes people who inject drugs.
There are many actions National Societies can take to facilitate programme implementation:
■ Educate volunteers and staff about drug use including injecting drug use in the general com-
munity and in prisons, HIV/AIDS and harm reduction strategies. Education will also counter
the stigmatization of and discrimination against IDUs and PLWHA and will empower
National Society members to be informed advocates for the reform of laws and policies relat-
ed to injecting drug use and to effectively implement harm reduction programmes.
37Spreading the light of science
64 See Annex II for more information on drug characteristics and effects.
A
us
tra
lia
n 
Re
d 
C
ro
ss
A
nd
re
w
 M
ac
C
ol
l/
Fe
de
ra
tio
n
■ Organize workshops and seminars on relevant subjects including detainees, HIVAIDS and the
role of the National Society.
■ Make an effort to get the support of policy-makers at the national and local levels by explaining
the importance of harm reduction programme to senior government officials at all opportune
moments and in all forums. For example, the members of the National Society executive
committees and boards are often ex-senior government officials or well-respected members of
society. These channels should be used to deliver messages on the necessity of introducing harm
reduction programmes.
■ Advocate for harm reduction programmes through social marketing campaigns, resource
mobilization and human resource development programmes.
■ The effective implementation of harm reduction programmes partly depends on the active
involvement of IDUs. In an environment of repressive laws and policies as well as stigma and
discrimination, IDU participation is likely to be minimal. Yet, National Societies can
contribute to creating an enabling environment: 
■ Organize regular discussion forums with law enforcement bodies such as the police, judges and
other judicial officers. Explain the importance of harm reduction programme in the prevention
and control of HIV. Such forums can be used to give updates on the implementation of
programmes including the successes and setbacks, while seeking their participation in finding
solutions to obstacles.
■ Identify key or respected community leaders or members and engage them in the development
and design of harm reduction programmes, in regular discussions on the success and challenges
encountered in programme implementation as well as ways of addressing stigma and
discrimination.
■ National Societies can provide space in their buildings for IDU self-help groups.
■ Establish coordinating bodies including policy-makers, public authorities, service providers,
representatives of service users, relevant NGOs and community-based organizations at national
and local levels to help streamline the efforts of organizations to avoid duplication of efforts,
and share experiences and information for synergy.
■ Incorporate monitoring and evaluation as part of the development of harm reduction
programmes. Indicators and systems for information collection and analysis need to be defined
during the programme development phase. Effective monitoring will indicate in a timely
manner programmatic weaknesses so that they can be addressed and rectified. Such measures
positively contribute to the effective, efficient and transparent management of programmes and
assist in achieving programme objectives. Such monitoring and evaluation will produce lessons
learned and perhaps good practices which can be disbursed across the Movement.
Section 3.5
Advocating harm reduction 
programmes
In many countries, the transmission of HIV is being fuelled by people sharing injecting equipment.
And still, there are no supportive policy and legal framework for the development and
implementation of harm reduction programmes. In light of the alarming scenarios seen in eastern
Europe and Asia, there is a compelling reason for strongly advocating governments to introduce
harm reduction programmes.
National Societies in partnership with other organizations can play a useful role in conducting
advocacy for the acceptance, introduction and maintenance of harm reduction programmes. In this
process it is important to identify issues that National Societies focus on.
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3.5.1 Changing society views
Societies have views about IDUs that do not reflect an under-
standing of why people become involved in drug use and the asso-
ciated risks. Negative or uniformed views may be reflected in mar-
ginalization or harassment of, stigmatization or antipathy towards,
or discrimination against IDUs. To change such views requires: 
■ conducting a short survey to understand society’s views and
perceptions of drug use and IDUs; and
■ based on the findings of the surveys prepare appropriate
messages that can positively influence social views and per-
ceptions, including countering misunderstandings and mis-
information. This work aligns naturally with existing work
to promote humanitarian values and should involve IDUs.
Possible action that National Red Cross Red Crescent Societies can take:
■ Educate volunteers and staff about drug use including injecting drug use in the general com-
munity and in prisons. Also educate about HIV/AIDS and harm reduction strategies to pro-
mote humanitarian values and counter stigma of and discrimination against IDUs.
■ Involve current and ex-IDUs as well as PLWHA in the design and implementation of the advo-
cacy process.
■ National Societies can provide space in their buildings for IDU self-help groups.
■ Develop key messages on injecting drug use in the community and in prison, and on
HIV/AIDS and harm reduction.
■ Identify community and government leaders and organize briefing sessions to make them
aware of issues faced by IDUs and ways to deal with these, including harm reduction strategies
and countering stigma and discrimination.
■ Through the oriented key society leaders, and using the key messages, facilitate educational ses-
sions for the community.
■ Facilitate ongoing dialogue with community leaders on harm reduction strategies, including
with leaders of faith-based organizations and ethnic and marginalized groups.
■ Promote dialogue for a supportive policy and legal framework through discussions with key
community members and others such as academics and activists.
■ Use public forums and, in particular, the mass media to explain what harm reduction is, its
benefits, the underlying rationales and its cost effectiveness.
■ Disseminate information through the media to the general public about harm reduction pro-
grammes during national, regional or global events such as conferences, on 1 December –
World AIDS Day, 8 May – World Red Cross and Red Crescent Day.
■ Coordinate public debate with professional associations including teachers, lawyers, law
enforcement and medical, as well as human rights centres, known activists and NGOs.
■ Research which obligations with regards to IDUs and harm reduction the government has rat-
ified freely in human rights treaties. What obligations did the government agree to through the
UNGASS Declaration? Did the government undertake obligations in the Ottawa Charter on
Health Promotion, 1986, the Cairo Programme of Action, 1994, the Habitat Agenda, 1996,
the Copenhagen Declaration, 1999, or other United Nations Conference Declarations? What
are the country’s obligations derived from the World Health Assembly’s Declaration, Health for
All in the 21st Century, 1998? What plans or promises has it made in national HIV/AIDS
strategies? Make these public.65
■ Advocate for health services that promote a range of options for people choosing to discontin-
ue drug use.
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Convey the message: Bosnia and Herzegovina
‘Drugs are not having the last word’, was the topic of a press conference and round table discussions
organized by the Red Cross of Bosnia and Herzegovina on 8 May – International Red Cross and Red
Crescent Day. “The subject has been on the Red Cross agenda for the last few years,” says Lea
Kujundzic, head of the Red Cross international department. “And we use the Red Cross Red
Crescent Day to highlight the problem in our country, a problem which is on the way from east to
west.”
Two video clips aimed at prevention of drug abuse have been developed and shown on the national
television. A large ceremony took place for the representatives of diplomatic missions and partners
from among NGOs devoted to these latest Red Cross activities.
Confront stigma and discrimination: Viet Nam
The Red Cross in Viet Nam has been including IDUs in the groups of youth receiving education
and skill development regarding HIV prevention. It has been a challenge to reach out and include
IDUs as the government’s ‘social evils’ approach promotes the idea that IDUs are to be feared and
shunned, rather than helped. One community even refused the Red Cross use of the community hall
if IDUs were included in the HIV education sessions. Rather than sacrifice the fundamental
principles of the Red Cross and Red Crescent, the Red Cross in Viet Nam conducted the session
under a tree in the village.
Use the media: Italy
The Villa Maraini, a foundation of the Italian Red
Cross in Rome, has been providing treatment to drug
users within the framework of the Italian Red Cross for
more than 25 years. By advocating for better treatment
of IDUs by police forces, it is creating an enabling
environment for harm reduction activities to be carried
out. And this means less HIV transmission. The
foundation advocates for humane treatment to reduce
human suffering – respecting that all drug users are
different and that addiction is a disease that requires treatment in just the same manner that other
diseases require treatment.
The foundation is fighting the stigma faced by drug users in Italy using the mass media. Five police
officers, who are also world or Olympic sports champions, have appeared in advertisements organ-
ized by Villa Maraini advocating for the humane treatment of drug users. Now that the police force
fully understands the issues that surround drug use, they have been more capable of understanding
the harm reduction approach.
3.5.2 Influencing policy-makers
The lack of a supportive legal and policy framework is the greatest obstacle to the acceptance, intro-
duction and maintenance of harm reduction programmes. In many countries, the relationship
between the spread of HIV and drug use is ignored, disbelieved or neglected. In some countries, dia-
logue on policy reform rarely takes place. 
Drug policies in many countries do not focus on public health issues such as HIV/AIDS. Conversely
HIV/AIDS policies often do not address injecting drug use. Often governments and development
agencies place priority on funding long-term solutions to drug use undermining efforts to reduce the
more immediate harm caused by the transmission of infections such as HIV through sharing inject-
ing equipment.
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Informing policy-maker’s views requires several factors:
■ Involve current and ex-IDUs as well as PLWHA in the advocacy process so as to present their
views and to give a human face to the issues.
■ Present evidence that despite repressive laws and policies in some countries concerning the
supply, demand and use of drugs over decades, drug use and injecting drug use is increasing.
■ Present evidence that drug use is present in the society, including information on the role of
injecting drug use in prisons in facilitating generalized HIV epidemics.
■ Present the evidence about the role of sharing of injecting equipment increasing the incidence
and prevalence of HIV, HBV and HCV in the community and in prisons.
■ Present the evidence that harm reduction programmes prevent HIV transmission and other
blood borne infections in the community and in prisons.
■ Present evidence that harm reduction programmes do not increase the level of drug use in the
community and in prisons.
■ Present evidence that harm reduction programmes are cost effective.
■ Present the government with information on its human rights obligations, particularly in
relation to health, which it has freely entered into, and how these relate to injecting drug use
and HIV.
■ As part of promoting humanitarian values, assert that while an IDU-related HIV epidemic may
be less visible than a famine or natural disaster, the government’s obligations in the face of
human suffering and death are similar.
There are several possible actions National Red Cross and Red Crescent Societies can take:
■ Involve current and ex-IDUs as well as PLWHA in the design and implementation of the
advocacy process so as to present their views and to give a human face to the issue.
■ Gather scientific evidence on harm reduction programmes and their success and present it to
decision-makers through all possible channels.
■ Gather good practices and lessons learned from other harm reduction programmes in country
and from other countries to present to government and communities.
■ Advocate with the government to repeal laws on the non-provision of condoms, needles and
syringes in the community and in prisons.
■ Advocate for the introduction of appropriate drug use and related education programmes for
families of prisoners and juvenile detainees.
■ Advocate with governments to expand the range of non-custodial sentencing options for
persons convicted of drug use and, where appropriate, related charges.
■ Support AIDS education, voluntary and confidential testing for HIV infection, pre- and post-
test counselling and awareness programmes for IDUs.
■ Develop youth peer education programmes and outreach for people who inject drugs.
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■ Develop peer education programmes specifically targeted at the use of drugs, including inject-
ing drugs, for recreational use at parties and raves.
■ Research the human rights treaties the government has ratified; the obligations which it has
undertaken in the UNGASS Declaration and Ottawa Charter on Health Promotion (1986) as
well as the plans laid out in national HIV/AIDS strategies. Advocate for the government to ful-
fil its obligations particularly with regards to IDUs and harm reduction.
■ Negotiate with governments to undertake pilot harm reduction programmes.
■ During international or national events that have wide media coverage, focus on one or two
key messages so as to provide a sustained, coherent message. For example, see Annex III, the
International Federation press releases from the International Conference on Reduction of
Drug Related Harm, Thailand, 6-10 April 2003.
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Heroin
■ First discovered by a British chemist in 1871, heroin or diacetylmorphine is produced by bond-
ing opium’s active ingredient, morphine, obtained from the opium poppy, with a common
industrial acid, acetic anhydride. By the end of the 19th century heroin was being mass pro-
duced and used as a broad spectrum pain killer. It was believed to be a safe, non-addictive mor-
phine substitute.
■ Heroin can be administered by injection, sniffing (snorting), or smoking and is highly physi-
cally addictive and produces lasting psychological dependence.
■ Depending on the availability of heroin and the finances of the user, heroin is commonly
injected about three times a day with effects lasting from three to six hours. 
■ Common behaviours following administration include an increased sense of euphoria and
sleepiness, lethargy, docile appearance and possibly a shuffling gait.
■ Acute withdrawal symptoms commence within 8 to 12 hours after the last dose. Though these
are generally not life threatening they can be very severe, including gastrointestinal discomfort,
muscle cramps and flu-like symptoms. In some people, withdrawal symptoms can be so severe
that when some users obtain heroin, they may inject as rapidly as possible, sometimes without
concern for possible HIV, hepatitis B or hepatitis C infection.
■ Associated health problems of long term heroin use can be collapsed veins, abscesses, tetanus,
HIV/AIDS, hepatitis B, hepatitis C, heart, chest and bronchial problems and constipation.
Overdose risk is independent of length of use.
Opium
■ The sole source of opium is the opium poppy, Paperver somniferum. The psychological and
healing effects of opium have been known for around 4,000 years.
■ By incising the head of the opium poppy, farmers can extract its sticky brown sap from the egg
shaped bulb. The raw opium sap contains 7-15 per cent morphine, which easily can be pre-
cipitated from the poppy sap after simple boiling. Raw opium has a characteristic odour which
is strong and pungent.
■ Opiate receptors in the brain induce high physiological addiction and lasting psychological
dependence. Regular use results in increased tolerance and the need for greater quantities of the
drug.
■ Use of opium in developed countries has decreased substantially but it is still widely used
among highland ethnic minorities in China, Laos, Cambodia, Myanmar, Thailand and Viet
Nam both for recreational and medical purposes.
■ Can produce intense euphoria, a heightened state of well-being, enhanced imagination and
speech. Soon after, respiration slows down, imagination diminishes and the thinking process
becomes confused. Lethargy, relaxation and deep sleep usually follow.
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Drug characteristics 
and effects 66
66 The information in this annex is adapted from the Manual for Reducing Drug Related Harm in Asia, The Centre for Harm Reduction, Macfarlane Burnet Centre for
Medical Research and Asian Harm Reduction Network, 2003.
■ Administration is usually by smoking but it can also be chewed and cooked with food for diges-
tion. Particularly in countries of origin, it can be drunk as an infusion.
■ The opium pipe has a long thick stem with a bowl at one end. The opium ‘pellet’ is placed into
the bowl, heated and the smoke is inhaled.
■ Sediment or the ‘dross’ left in smoking implements can contain up to 8 per cent morphine, is
often used again and is known as black water opium. This form of opium still remains popu-
lar in particular Asian countries, i.e. Viet Nam and Cambodia.
■ Smoking puts more of the active ingredients of opium into the blood stream faster, by the way
of the lungs, so the drug begins to reach the brain in about seven seconds.
■ Long-term use results in decreased mental and physical capacities with loss of appetite and
body wasting.
■ Withdrawal symptoms, similar to those of morphine, include agitation, irritability, anxiety,
restlessness, insomnia, and abdominal and muscle pain.
Morphine
■ Morphine is a naturally occurring substance in the opium poppy, Papaver Somniferous.
Morphine is most commonly found as morphine sulfate and morphine hydrochloride. Both
are fine white crystalline powders, bitter to the taste. Both are soluble in water and slightly sol-
uble in alcohol.
■ Morphine is a potent narcotic analgesic, and its primary clinical use is in the management of
moderately severe and severe pain.
■ Morphine is administered by several routes (injected, smoked, sniffed, or swallowed); but when
injected intravenously, morphine can produce intense euphoria and a general state of well-
being and relaxation.
■ Regular use can result in the rapid development of tolerance to these effects. Profound physi-
cal and psychological dependence can also rapidly develop, and withdrawal sickness upon
abrupt cessation of morphine use; many of the symptoms resemble those produced by a case
of moderately severe flu.
■ Irregular or intermittent users (who are not substituting the drug for another narcotic anal-
gesic) may start and continue to use doses within the therapeutic range (i.e. up to 20 mil-
ligrams). However, regular users who employ morphine for its subjectively pleasurable effects
frequently increase the dose as tolerance develops. To take several hundred milligrams per day
is common, and there are reliable reports of up to four or five grams (4,000-5,000 mg) per day.
■ Duration of effect is four to five hours.
Methadone
■ German chemists first produced methadone in the early 20th century and it has been used clin-
ically since the end of the First World War.
■ It is a powerful synthetic opiate like heroin and morphine but without the strong sedative
effect. It can substitute for heroin and is widely used by doctors in the treatment of heroin
addiction.
■ In its basic form it is a white crystalline powder. It is generally administered as a syrup, mixed
with cordial or fruit juice and taken orally. Methadone is also available in an injectable form.
Users have been known to inject the syrup which can result in health problems.
■ Effects are felt within one hour of a dose, with the peak effect felt at four to eight hours after
the dose. The effects of methadone last longer (usually up to 24 hours) than heroin and there-
fore administration is usually once a day.
■ Doses vary for different people and from the commencement of treatment the dose is gradually
increased while observing the level of tolerance and avoiding the onset of heroin withdrawal.
Once treatment has stabilized, daily dosages can vary from 40 milligrams to over l00 milligrams.
■ If the dose is too low opiate withdrawal can occur resulting in symptoms such as abdominal
cramps, nausea and vomiting, irritability and back and joint ache. Too high a dose can be indi-
cated by such symptoms as drowsiness, nodding off, shallow breathing and pinpoint pupils.
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■ Other side effects that can occur but are unrelated to the dose can include, sweating, constipa-
tion, aching muscles and joints, decreased sex drive, fluid retention, loss of appetite and tooth
decay.
■ Methadone can lead to dependence but it is generally considered less serious than heroin and
morphine dependence and is easier to treat. People can stop using methadone by reducing their
dose gradually, by not setting a time to achieve this goal, and by consulting the counsellor/doc-
tor involved in the methadone programme about what is involved.
■ Sudden withdrawal is not recommended as the discomfort encountered can result in people
using heroin again regularly.
Cocaine
■ Inhabitants of South America have a history of chewing the coca leaf for thousands of years but
it has only been known to the Europeans since the 19th century. The coca leaf affects a num-
ber of neurotransmitter systems in the brain and is active on various anatomical sites within the
central nervous system.
■ Cocaine is produced by chemical processing and treatment of the coca plant which transforms
the leaves into coca paste. Paste is treated with hydrochloric acid to remove impurities and
results in white, crystalline substance, cocaine hydrochloride.
■ It is the most potent of the stimulants.
■ In the form of leaf chewing or brewed tea the drug is believed to be virtually harmless bur it is
rarely available in this form outside of South America.
■ Disagreements exist among authorities and researchers as to the addictive nature of cocaine.
While some state there is a high risk of developing physical and psychological dependence,
many researchers suggest that cocaine does not produce physical dependence.
■ Methods of administration include snorting by intranasal inhalation (onset of effects two to
four minutes); smoking or ‘freebasing’ (burning the crystals and smoking the vapours; onset of
effect 15 seconds); and injection (onset of effect 15-20 seconds).
■ Effects can last from 10 to 40 minutes depending on the purity and the route of the adminis-
tration.
■ Typical behaviours during the effect include hyperactivity, exhilaration, increased energy, alert-
ness, confidence and sexual activity. The user may also have unpredictable behaviour, feel
invincible and be both quarrelsome and aggressive.
■ A fatal condition can result from sensitivity to the drug or massive overdose.
■ Several hours after last use, feelings of agitation and depression can occur.
■ There is a high risk of HIV transmission since typical IDUs of cocaine require more injections
than heroin, and high incidence of sharing of needles and unprotected, prolonged sexual inter-
course.
Cannabis
■ Cannabis is a psychotropic product from the plant Cannabis sativa. It is believed to have been
used for thousands of years for medical, religious and social reasons. The stem of the plant (non
potent form of cannabis) is used in the manufacture of hemp rope, string, paper, textiles and
clothing.
■ There are male and female plants. The strongest concentration of the psychoactive chemical,
Tetrahydrocannabinol or THC, is found in the flowering shoots of the female plant.
■ A widely used drug with a relatively low potential for harm when compared to heroin, alcohol
and tobacco.
■ There are differing views by authorities on physical dependency of cannabis. Psychological
dependency can be associated with frequent cannabis use.
■ Three forms of cannabis exist: marijuana, hashish and hashish oil. Marijuana is the dried leaves
and flowers of the plant and is usually the least potent of the three. Hashish forms as a sticky oil
coating on the flowering tops of the plant which is collected and made into small blocks of dried
resin. The concentration of THC is greater thus producing a stronger effect. Hashish oil is the
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extraction from the resin of the cannabis plant and is the most powerful of all the cannabis forms. 
■ Marijuana is usually smoked in hand rolled cigarettes or in a pipe. The concentrated form of
hashish or hashish oil is often smoked with ordinary cigarettes or incorporated into food sub-
stances such as cakes and biscuits and ingested.
■ Effects vary due to a number of factors in relation to the person, method of administration,
cannabis form and frequency and period of use. Some effects can include euphoria, relaxation,
relief from stress and pain, increased appetite, impaired motor skills, confusion, loss of con-
centration and decreased motivation.
■ Effects normally reach their peak within 30 minutes and can last up to three hours. 
■ Withdrawal following long-term use can include headaches, anxiety, depression, and sleep dis-
turbance.
■ Like other burnt inhalations cannabis contains carcinogens, tar and carbon monoxide. This can
result in respiratory complications, cardiovascular effects and cancer. A single cannabis cigarette
contains the same amount of tar and other noxious substances as approximately 14-16 filtered
cigarettes.
Amphetamine
■ Originally synthesized in Germany in the late 19th century amphetamines were not patented
until the 1930s. In the 1940s the drug came into therapeutic use for a variety of medical con-
ditions such as epilepsy, depression and hyperkinetic children. Following the Second World
War, amphetamines were promoted quite readily.
■ Amphetamines have a stimulant action similar to the naturally occurring hormone adrenaline
which stimulates the activity of the central nervous system and increases the activity of the brain.
■ Amphetamines appear in a number of forms and when manufactured illegally can be found in
powder, tablet, capsules or liquid. Administration is by ingestion, injection, inhaled through
the nose and smoked when in the form of methamphetamine hydrochloride.
■ Most common illicit manufacturing of amphetamine is in the form of methylamphetamine.
The most common starting material for methylamphetamine is ephedrine, which is a legal sub-
stance, is readily available in tablets or capsules and is sold as a decongestant.
■ Self medication with amphetamine is common among truck drivers, students, fishermen, and
businessmen to stave off normal fatigue, enabling them to work for days with little sleep or food.
■ Effects usually wear off after three to six hours and the user can become suddenly tired, irrita-
ble, depressed and unable to concentrate. Methylamphetamine ‘ice’ when smoked can have an
effect of between 2 to 16 hours depending on the amount taken.
■ Effects from amphetamines vary and depend on dosage, mode of administration, the individ-
ual, and the circumstances in which the drug is taken.
■ Low doses can result in a sensation of euphoria, heightened alertness, increased energy and
activity, reduced appetite and self confidence. Long-term use can lead to malnutrition, exhaus-
tion, depression and psychosis. Death from stimulant use is rare but is more likely to occur with
intravenous injection.
■ Tolerance can be pronounced where a long-time user may need 20 times the initial dose to pro-
duce the same effect. 
■ Has a reputation for facilitating social and sexual interactions which has implications for poten-
tial HIV risks as enhanced sexuality may not be accompanied by safer sexual practices.
■ Withdrawal symptoms during the initial period may be acute exhaustion, and for a regular user,
it may be followed by irritability, lethargy, deep depression, anxiety attacks and episodic 
craving.
Ecstasy or Methylenedioxymethamptamine (MDMA)
■ Although first patented in Germany in 1914 as an appetite suppressant, it was never market-
ed. In the 1970s it was used by psychiatrists in the United States as a valuable and safe aid to
counselling and therapy, until it was banned in the mid 1980s. Since the 1990s it was com-
monly associated with dance parties and other social activities, including sex.
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■ Closely related to both amphetamines and hallucinogens it is often described as a psychedelic
drug with stimulant properties.
■ Appears as tablet (most frequently seen), capsule and powder form.
■ Preferred administration is by swallowing although there are reports of experimentation by
injection and inhalation.
■ Taken orally the effect will commence between 30 to 60 minutes and may last for several hours.
■ The immediate effects can be a ‘rush’ of euphoria, followed by a general sense of peacefulness
and heightened sensual awareness. Inhibition can disappear, there is increased self esteem and
confidence, and improved trust and communication between friends can occur. Adverse effects
can include dry mouth and throat, jaw clenching, increased heart rate and blood pressure.
■ Overdose can result from very high blood pressure, increased heart beat and body temperature
(overheating). Deaths have been reported from fluid imbalance either by dehydration or water
overloading.
■ A ‘high’ can be followed with fatigue, anxiety and a depression which may last several days.
■ Tolerance can develop with continued use and some dependence is thought to occur. Little is
known about long-term effects but it has been suggested that it may damage some types of
brain cells.
Hallucinogens
■ Hallucinogens also known as psychedelics, act on the central nervous system to produce sig-
nificant, often radical, changes to the user’s state of consciousness; can distort the user’s sense
of reality, time and emotions. First synthetically produced in the 1940s to remove obstructive
inhibitions in psychiatric cases. Those derived from plants, such as the peyote cactus, have been
used by indigenous groups of Mexico for hundreds of years for recreation and religious obser-
vations. Other hallucinogens include mescaline (natural product from the peyote cactus), nut-
meg and mushrooms (containing the drugs psilocin and psilocybin), dimethyltryptamine
(DPT), phencyclidine (PCP) and ketamine hydrochloride.
■ Lysergic acid diethylamide (LSD) is the best known of hallucinogens. It is a synthetic drug based
on an ergot which has been extracted from a dry fungus that grows on rye grass. The manufac-
turing of LSD from precursor drugs requires a high level of technical knowledge and expertise.
■ LSD is an odourless, colourless and tasteless liquid which is often absorbed into any suitable
substance such as blotting paper and sugar cubes or can be incorporated into a tablet, capsule
or occasionally confectionery. Its most popular form is on absorbent sheets of paper which are
then divided into squares and taken orally.
■ Unlike many other drugs, LSD users can have little idea of what they are embarking on and
the effects can vary from person to person, from occasion to occasion and the dose.
■ Effects can begin within one hour, build up between two to eight hours and slowly subside after
about 12 hours.
■ For many LSD users the effect can be extremely enjoyable, relaxing and promote a sense of
well-being. There are often changes in perception, of sight, sound, touch, smell, taste and
space. Negative effects can include loss of emotional control, disorientation, depression, dizzi-
ness, acute panic and feelings of being invincible resulting in a person physically placing them-
selves in danger.
■ Long-term use can result in flashbacks of hallucinogenic effects, days, weeks or months after
using the drug.
■ There is no evidence of physical dependence and no withdrawal symptoms have been observed
even after prolonged use. However, psychological dependence can occur.
■ Tolerance to LSD can develop rapidly but tolerance can also disappear after five to six days
when not used on a regular basis.
Nicotine/tobacco
■ Known to be used by Native Americans in religious and social occasions 1,000 years ago.
Introduced to Europe in the 17th century where it was used for recreation and medicinal pur-
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poses. Tobacco consumption expanded with the introduction of milder forms of tobacco, auto-
matic cigarette rolling machines, massive advertising campaigns and when governments saw its
potency as a source of revenue.
■ Nicotine, found in tobacco, is one of the most addictive substances known. Nicotine is a cen-
tral nervous stimulant that disrupts neurotransmitter balance. Physical dependence on nicotine
and more importantly, psychological dependence on cigarettes, develops quickly.
■ Tobacco inhalation results in nicotine affecting the central nervous system (CNS) in about ten
seconds. With the chewing of tobacco, it takes upwards of five minutes to affect the CNS.
■ The effect of nicotine when tobacco is consumed in the form of smoking, chewing or as snuff is
the constriction of blood vessels, raising of the heart rate, and blood pressure, decreased appetite,
producing mild emphysema, partially deadens sensation of taste and smell and irritates the lungs.
Prolonged use of tobacco can cause lung, heart and blood vessel damage and cancer.
■ The World Health Organization estimates that smoking is responsible for one out of five
deaths, or 3 million deaths per year. Research has shown that over 50 per cent of smokers will
die prematurely as a direct result of tobacco induced illnesses.
■ Tolerance to the effects of nicotine develops rapidly, faster than that of heroin and cocaine.
■ Withdrawal, after long term-use can result in headaches, severe irritability, inability to concen-
trate, nervousness and sleep disturbance. Nicotine craving may last a lifetime after withdrawal.
■ For the very physically dependent, nicotine patches are provided in a relatively harmless form
avoiding the injurious affects of tobacco smoke such as carbon monoxide, tar, soot and other
by products.
Solvents, inhalants and volatile substances
■ Since ancient times, people have inhaled the vapours of perfumes, ointment and burning spices
as part of their religious ceremonies. Solvent misuse, as we know it, emerged during the 1950s
in the United States and has since spread to most parts of the world.
■ Three main types of inhalants are organic solvents, volatile nitrates including amyl nitrate –
poppers, which are used for sex and dancing, and nitrous oxide.
■ Some of the most common inhalants include glue, aerosol spray cans, paint thinner, petrole-
um products, chrome based paint and felt pens.
■ Inhalation is either through the mouth or nose. Often the product is sprayed into a plastic bag
or soaked onto a rag and then inhaled or it is inhaled directly from the container.
■ Inhalants are absorbed through the lungs into the blood stream, which then carries the chem-
icals rapidly to the brain. They slow down the activity of the brain and central nervous system.
Intoxicating effects are often quick acting (seven to ten seconds), intense and short lived, last-
ing no more than 30 to 60 minutes (some inhalants only last two minutes).
■ Effects can include excitement, dizziness, stupor, disorientated and uncoordinated, visual dis-
turbance and slurred speech. Prolonged use, particularly leaded petroleum products, can lead
to brain, liver, kidney, and especially lung damage. Death can arise from respiratory arrest and
cardiac irregularities.
■ Organic solvents are often readily available, inexpensive and are commonly used by young peo-
ple in their first few years of secondary schooling.
Alcohol
■ Alcohol is the most commonly used psychoactive drug globally and the oldest. Historical ref-
erences abound in literature, religion and science about alcohol, its effects and its consequences.
■ The production of alcohol results from a process of fermentation, in which water and yeast act
on the sugars of various types of grains, vegetables and fruit. The psychoactive drug that is pro-
duced is ethyl alcohol.
■ As a depressant drug, alcohol slows down the activity of the central nervous system and in small
doses can result in people being relaxed, with inhibitions being lowered. As the depressant
effect takes over, it can slow reflexes, depress respiration and heart rate and disrupt reasoning
and judgment. 
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■ Heavy drinkers usually develop a tolerance to alcohol and need to drink more to experience the
same effect.
■ Regular drinking can result in psychological and physical dependency.
■ The long term effects of alcohol on the body, following heavy drinking over a long period of
time, are extensive. These can include higher blood pressure, enlarged heart, cirrhosis of the
liver, liver swelling and pain, skin bruising, stomach and intestinal ulcers, muscle weakness, loss
of memory, loss of sensation in feet and hands and foetal damage if pregnant. 
■ Behavioural problems are commonly linked to alcohol. Some problems can include family vio-
lence, work absenteeism, motor accidents, legal problems and fines associated with violent
assaults and financial difficulties.
■ A physically dependent person will suffer withdrawal symptoms that can include loss of
appetite, irritability, confusion, inability to sleep, cramps, tremors, hallucinations and even
death due to seizures.
■ Addiction to alcohol is a chronic progressive disease that is distinguished by lack of control over
drinking, preoccupation with alcohol use despite adverse consequences and denial. If not con-
trolled it can be fatal. While alcoholism can take years to develop the recovery period can take
a lifetime.
Benzodiazepines
■ This class of synthetically-based drugs was developed in the late l940s and 1950s as an alter-
native to barbiturates. In the West they came into wide clinical use in the 1960s and the 1970s.
The drugs were looked upon as an innovation in the treatment of anxiety disorders and sleep-
ing problems.
■ Benzodiazepines are a chemical group term and are classified as sedatives or tranquillizers.
Benzodiazepines combine with certain parts of the nerve cells in the brain to enhance inhibito-
ry mechanisms. They induce a state of calmness, slowing down physical, mental and emotion-
al responses. When given in large doses they will induce sleep. The increasing number of drugs
includes Temazepam, Diazepam, Nitrazepam, Oxazepam, Clonazepam and Flunitrazepam.
■ Administration is usually in tablet, capsule or liquid form and taken orally or by injection. The
calming effect is evident in about 45 minutes and some degree of sedation can persist for 24
hours.
■ Adverse side effects can include lethargy, confusion, mood swings, nausea, dizziness, disturbing
dreams and slurred speech. The over prescribing or individual misuse of such drugs can result
in increased anxiety, irritability and hostility. Mixed with other drugs they can reduce judgment
of time, space and distance and combined with alcohol can result in death.
■ After a high dose continued for about two months or a low dose taken for a year or more, with-
drawal can be extremely severe and prolonged. Feelings of craving for the drug, anxiety, sleep
disturbance and possible hallucinations can occur. Withdrawal symptoms can erratically come
and go in cycles separated by two to ten days and may persist for several months after the drug
has been stopped.
Anabolic steroids
■ Performance enhancing drugs have been documented throughout human history. In the 1920s,
testosterone (male hormone) was isolated and by the First World War was being administered
to troops to overcome fatigue and injuries. Since the 1950s, testosterone has been synthetical-
ly produced and its use was soon associated with athletic performance.
■ Anabolic steroids are a group of synthetic compounds which are structurally related to the nat-
ural male hormone testosterone. They produce anabolic activity (greater muscular bulk result-
ing in increased muscular strength) by increasing protein synthesis and androgenic activity
(enhanced secondary sexual characteristics).
■ Administration is by intravenous or intramuscular injection and orally.
■ Injectable forms are designed to be longer acting than orals and are released slowly over time.
The high rate of administration via injection has raised the concern and risk of HIV, hepatitis
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B and hepatitis C. Primarily taken to increase muscle mass, they can also allow a user to train
harder, promote a quicker recuperation phase and increase the healing process for some types
of injuries.
■ Early effects can include increased confidence and energy, enhance motivation and enthusiasm,
increased aggression and sexual appetite. Larger doses can result in a loss of inhibition, lack of
judgment and mood swings. Prolonged users frequently become quarrelsome and aggressive.
Severe prolonged use can result in heart disease, liver damage, mental disorders and violence.
■ Physical addiction is not believed to occur but some users do become psychologically depend-
ent, believing their physical and sporting achievements will be reduced without them.
■ Withdrawal symptoms can include severe depression, insomnia, lethargy, loss of appetite,
headaches and craving.
Barbiturates
■ Barbituric acid, a combination of urea and malonic acid, the base material of barbiturates, was
first synthesized in 1863 by Adolph von Bayer. In 1903, barbiturates were first synthesized as
a sedative for nervousness.
■ Barbiturates are a prescription drug in a white bitter tasting powder soluble in water.
■ Barbitates are swallowed as tablet, capsule or liquid solution. They can also be inserted as a
rectal suppository or injected into bloodstream (mainlining) or muscle, or under skin (skin
popping).
■ Effects include relaxation, peacefulness, sleepiness, pleasurable intoxication, dizziness, inactivi-
ty, withdrawal, interrupted thought process, mood swing, excitement, increased pain, hostility,
depression, anxiety, confusion, changed vision, increased sex drive, intense emotions, hangover.
■ Barbiturates depress the central nervous system and result in a progressive decline in blood
pressure, heart rate and breathing. They can produce nausea, vomiting, abdominal pain, alter-
nate pupil constriction and dilation, loss of reflex response, low body temperature and blood
temperature, and weak pulse.
■ Tolerance builds quickly, which requires increasing the dose to maintain the effects of barbitu-
rates. Craving continues after pleasurable effects disappear and drug use is stopped.
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Annex III Press releases
Red Cross Red Crescent calls on gov
ernments to end 
‘social evil’ policies that fuel HIV/AI
DS, 5 April 2003.
Governments need to stop treating people
 who are at high risk from HIV/AIDS as 
‘social evils’ and
urgently address the stigma, discriminatio
n and marginalization of these groups if gl
obal efforts to com-
bat the disease are to be achievable, said 
the International Federation of Red Cros
s and Red Crescent
Societies. 
The call comes on the eve of the 14th Int
ernational Conference on the Reduction o
f Drug Related
Harm in the northern Thai city of Chia
ng Mai, which runs between 6-10 April.
 The conference, of
which the International Federation is a co
-host, will address, among other issues, th
e negative impact of
‘social evil’ policies on preventing HIV 
infection. Among the groups generally t
argeted as a social
scourge, are injecting drug users and com
mercial sex workers.
“We need greater recognition worldwide o
f the fact that by ostracizing and margina
lizing groups of
people, they are made especially vulnerab
le to disease. We know that by being sing
led out as deserving
punishment, the unsafe practices of injec
ting drug users are being driven undergro
und, resulting in a
public health disaster”, said Massimo Ba
rra, founder of an Italian Red Cross fou
ndation that assists
injecting drug users, and board member o
f the Global Fund to Fight AIDS, Tubercu
losis and Malaria. 
Southern Europe and communities in Nor
th and South America and Australia, have 
previously expe-
rienced explosions in HIV epidemics throu
gh the use of shared injecting equipment. E
astern Europe and
parts of Asia in particular, are today witn
essing alarming rates of HIV infection th
rough shared inject-
ing drug equipment. In Eastern Europe,
 which has the fastest growing HIV/AID
S epidemic in the
world, HIV rates have soared by 1300 pe
r cent since 1996 while in Russia, up to 9
0 per cent of regis-
tered infections have been attributed to th
e use of shared injecting equipment.
“The only way to reverse this trend is for g
overnments to implement policies that see
 a deliberate shift
from social exclusion to social inclusion of
 injecting drug users. Reach out to them a
nd make their prac-
tices safe. Providing clean needles is a star
t,” added Barra.
Studies show that needle exchange progra
mmes have reduced high-risk behaviour a
mong injecting
drug users by as much as 80 per cent, wit
h an estimated 30 per cent or more reduc
tion in HIV infec-
tion rates. 
“There is clear scientific evidence that ne
edle exchange programmes work. They h
elp contain the
HIV/AIDS pandemic, and in a very cost 
effective way. Evidence is also clear that th
ese programmes do
not promote drug use,” said Bernard Gard
iner, head of the International Federation’
s HIV/AIDS unit.
The Red Cross and Red Crescent is alre
ady implementing such programmes in s
everal countries,
including Italy, Croatia, Latvia, Portugal a
nd Spain in collaboration with governmen
ts or other organi-
zations, while the Vietnamese and Chinese
 Red Cross have begun to include injecting
 drug users in their
HIV/AIDS prevention programmes. 
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Prevent war on drugs becoming wa
r on drug users, 
says Red Cross Red Crescent, 10 Ap
ril 2003.
It is becoming more urgent every day for
 governments to provide efficient and pra
ctical measures to help injecting
drug users lead healthy lives, such as increa
sed access to treatment and programmes th
at lessen the harm they are exposed
to, the International Federation of Red C
ross and Red Crescent Societies said today
. Harsh and even violent policies to
force individuals to change, only shift th
e war on drugs to a war on drug users, 
it added at the closing of the 14th
International Conference on the reduction
 of drug-related harm in Chiang Mai, Tha
iland. 
HIV-rates among injecting drug users wh
o share needles and syringes are rapidly in
creasing – in many countries the
infection rates have exploded to epidemic
 levels in less than one year. Most injectin
g drug users are already a disenfran-
chised population at high risk to HIV inf
ection, and face high levels of stigmatizat
ion, discrimination and even incar-
ceration. 
Support to these groups is imperative, sai
d Dr. Massimo Barra, who founded an It
alian Red Cross foundation that
assists injecting drug users, and board me
mber of the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. 
“If we do not recognize, respect and appr
opriately provide available and proven tre
atment strategies to people who
use drugs, if we react in ways that aggravat
e the suffering, then we are perpetuating a
n attitude that goes against the con-
cept of humanity and human rights – as 
well as against the interests of each nation
. Easier access to clean needles and
syringes, drug substitution and treatment
 programmes is a humanitarian gesture, 
not an act of complicity,” said Dr.
Barra.
Hundreds of scientific studies around the 
world have demonstrated the effectiveness
 and cost benefit brought about
by harm reduction strategies, which often 
include needle and syringe exchange progr
ammes and drug substitution treat-
ment.
“The scientific evidence is clear: harm re
duction works. ‘Social evil’ policies, cond
emnation, harassment and even
incarceration of drug users do not,” said B
ernard Gardiner, manager of the Internati
onal Federation’s HIV Unit. “What
is urgently needed are treatment programm
es for those who can and want to stop usin
g drugs and effective harm reduc-
tion programmes to stop people from dyin
g. The stigmatization and discrimination 
of injecting drug users, particularly
those who are HIV-infected, continues to 
spread the virus around the world, also am
ong the groups who consider them-
selves at low-risk.”
Although many countries are already prov
iding quality services to address problem d
rug use, other governments have
instituted policies that hinder practical h
arm reduction work. A number of Red C
ross and Red Crescent societies in
Europe, Africa, Asia and the Americas are
 already running harm reduction program
mes in line with the International
Red Cross and Red Crescent Movement’s
 humanitarian mandate. Most of these pr
ogrammes build on the experiences
and views of current and former drug use
rs and HIV positive people, who through
 these programmes are involved in
the betterment of their communities and 
their own personal growth and human dig
nity. 
The Red Cross and Red Crescent aims to 
relieve the suffering of people all around t
he world, and it does this main-
ly by working in local communities. Red 
Cross helps people during times of war an
d peace, and also after natural dis-
asters, all of which today requires working
 towards protecting the basic social, econo
mic and cultural needs of all indi-
viduals regardless of their origin, beliefs or
 status.
The International Red Cross and Red Cr
escent Movement plays a unique role in p
rotecting the dignity of persons
affected by disease, in particular throug
h efforts to reaffirm the principles - H
umanity, Impartiality, Neutrality,
Independence, Voluntary Service, Unity, a
nd Universality - and values of internation
al humanitarian law. Discrimination
and intolerance continue to cause great suf
fering that affects individuals and societies
. There is widespread lack of respect
for international humanitarian law, huma
n rights and human dignity in the world
 today. Yet no person can be unde-
serving of the protection of the law. Resp
ect for the inherent dignity of the human
 person is a basic tenet of interna-
tional law. Moreover, the ultimate aim of 
any legal order should be to expand the p
rotection afforded to the individual. 
States and the components of the Move
ment are natural partners for humanitar
ian action. States recognize that
National Societies are autonomous organi
zations that play an auxiliary role in prov
iding humanitarian services side by
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side with the public authorities within their own countries. They are jointly responsible for preventing and alleviatinghuman suffering and for preserving the dignity of persons affected by disease and other harmful events or circum-stances.
IDUs are particularly vulnerable owing to discrimination, marginalization and social exclusion. Measures are need-ed to empower IDUs and to strengthen their capacity to respond to and cope with situations that threaten their dig-nity. In relation to HIV/AIDS, measures to ensure that IDUs have a voice and participate in decisions affecting them,and measures to improve their situation including harm reduction programmes and efforts to reduce the stigma anddiscrimination which IDUs face, are needed.
Effective partnerships between States, the components of the Movement, civil society and international aid agenciesare necessary in order to build capacity and mobilize resources in response to the HIV/AIDS epidemic and in relationto IDUs to implement comprehensive harm reduction programmes and policies, including legal reform.States and the components of the Movement should look to their commitment to action set out in the Plan ofAction of the 27th International Conference in order to raise awareness of humanitarian principles and values, andactively promote tolerance, non-discrimination, non-violence and respect for diversity among all peoples.
Red Cross Red Crescent welcomes Global Fund 
move to tackle HIV/AIDS among injecting drug 
users
A decision by the Global Fund to Fight AIDS, TB and 
Malaria (GFATM) to finance HIV/AIDS prevention an
d care
programmes among injecting drug users in Thailand an
d Russia, has been welcomed by the International Fede
ration of
Red Cross and Red Crescent Societies as a significant st
ep in tackling the issue. 
In welcoming this move, Dr Massimo Barra, a GFA
TM board member and veteran of the Italian Red 
Cross
HIV/AIDS and harm reduction response, also called fo
r more programmes that follow humanitarian and publ
ic health
principles. 
“The stigma attached to drug use is causing further mar
ginalization of this most vulnerable group and this is di
rectly
impeding efforts to prevent the spread of HIV. Forcing 
drug-users further underground and into situations whe
re trans-
mission of HIV/AIDS is more likely and denying them 
access to life-saving treatment and prevention services, i
s creating
a public health disaster,” he said.
“This happens even though the evidence from scientific
 and medical research on best practices and cost benefit 
analy-
ses is overwhelmingly in favour of harm reduction prog
ramming”.
The International Federation sees programmes tackling 
the transmission of HIV/AIDS through shared needle u
se and
the stigma and discrimination associated with it, as ess
ential to the battle against the pandemic. Red Cross so
cieties in
Europe, including Russia, have begun such initiatives, i
ncluding needle exchange and drug treatment.
The approval of the a US$ 1.38 million grant for Care T
hailand and US$ 88.7 million for a  non-governmental o
rgan-
ization (NGO) consortium in Russia came at a meeting
 of the GFATM board in the northern Thai city of Chi
ang Mai.
It is the first time that the Global Fund has backed ha
rm reduction efforts in South East Asia, parts of which
 are wit-
nessing an HIV/AIDS epidemic fuelled by injecting dru
g use.
Injecting drug user groups and NGO’s have participated
 in efforts to develop country specific programmes for G
lobal
Fund financing around the world, but have found it dif
ficult to convince some Ministries of the need for progr
ammes to
tackle HIV transmission through needle sharing. This d
espite injecting drug use being the main factor in the H
IV/AIDS
epidemic in areas such as Eastern Europe.
The grants to Thailand and Russia was one piece of pos
itive news emerging from this latest GFATM board me
eting.
The Fund is still dramatically short of money promised
 by rich countries to scale up the HIV/AIDS battle as a
greed at a
special UN General Assembly (UNGASS) two years ago
 in New York. In this funding round, fewer people will 
be given
access to anti-retroviral treatment through Global Fund
 money than on previous funding rounds, particularly i
n Africa.
This despite global targets to increase the number of pe
ople with access to HIV/AIDS treatment. 
“This is just not good enough. The Fund should be gro
wing – not shrinking,” said Bernard Gardiner, manager 
of the
International Federation’s global HIV/AIDS programme
. “At UNGASS, all countries agreed to specific objective
s to stop
HIV/AIDS. It is not only time to honour those promis
es to keep people alive, but imperative to do so.”
Federation news
PROTECTING HUMAN DIGNITY
Minutes adopted at the Cannes medical comference, April 1919.
The Fundamental Principles 
of the International Red Cross
and Red Crescent Movement
Humanity
The International Red Cross and Red Crescent Movement, born of a
desire to bring assistance without discrimination to the wounded on
the battlefield, endeavours, in its international and national capacity,
to prevent and alleviate human suffering wherever it may be found.
Its purpose is to protect life and health and to ensure respect for the
human being. It promotes mutual understanding, friendship,
cooperation and lasting peace amongst all peoples.
Impartiality
It makes no discrimination as to nationality, race, religious beliefs,
class or political opinions. It endeavours to relieve the suffering of
individuals, being guided solely by their needs, and to give priority
to the most urgent cases of distress.
Neutrality
In order to enjoy the confidence of all, the Movement may not take
sides in hostilities or engage in controversies of a political, racial,
religious or ideological nature.
Independence
The Movement is independent. The National Societies, while
auxiliaries in the humanitarian services of their governments and
subject to the laws of their respective countries, must always
maintain their autonomy so that they may be able at all times to act
in accordance with the principles of the Movement. 
Voluntary Service
It is a voluntary relief movement not prompted in any manner by
desire for gain.
Unity
There can be only one Red Cross or Red Crescent Society in any one
country. It must be open to all. It must carry on its humanitarian
work throughout its territory.
Universality
The International Red Cross and Red Crescent Movement, in which
all societies have equal status and share equal responsibilities and
duties in helping each other, is worldwide.
The International Federation 
of Red Cross and Red Crescent
Societies promotes the humanitarian
activities of National Societies among
vulnerable people.
By coordinating international 
disaster relief and encouraging
development support it seeks 
to prevent and alleviate 
human suffering.
The Federation, the National Societies
and the International Committee 
of the Red Cross together 
constitute the International 
Red Cross and Red Crescent
Movement.
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